Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
  
ACYWX -001/ VAC -046 
 
 
 
 
A Phase 1, double blind, randomized, controlled study to evaluate 
the safety and immunogenicity of a new Meningococcal Conjugate 
Vaccine containing serogroups A ,C,Y,W and X in healthy adults.  
 
 
 
 
Sponsored by:  
 
PATH  
 
Collaborating Partner  and Pharmaceutical Support :  
 
Serum Institute of India Private Limited (S IIPL) 
 
 
 
Principal Investigator:   
Dr. Wilbur H. Chen  
 
 
Version 4.0; 27 September  2016  
 
 
 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 2 of 106 TABLE OF CONTENTS  
LIST OF ABBREVIATION S AND ACRONYMS  ................................ ................................ .........  6 
PROTOCOL SIGNATURE P AGE  ................................ ................................ ..............................  8 
PARTICIPATING INSTIT UTIONS  ................................ ................................ ..............................  9 
STUDY SYNOPSIS  ................................ ................................ ................................ ..................  10 
1. BACKGROUND AND INTRO DUCTION  ................................ ................................ ..........  18 
1.1. Pathogen  ................................ ................................ ................................ ............... 18 
1.2. Burden of Disease  ................................ ................................ ................................ 18 
1.3. Meningococcal Vaccines  ................................ ................................ ..................... 19 
1.3.1.  Polysaccharide Vaccines ................................ ................................ ...........  19 
1.3.2.  Conjugate Vaccines  ................................ ................................ ..................  20 
1.3.3. Monovalent Conjugated Vaccine against Meningococcal Serogroup C 
(MenCCV)  ................................ ................................ ................................ . 21 
1.3.4.  Monovalent Conjugated Vaccine against Men ingococcal Serogroup A 
(MenAfriVac®) ................................ ................................ ...........................  21 
1.3.5.  Tetravalent Conjugate Meningococcal Vaccines (TCMV)  ..........................  23 
1.3.6.  Overall Impact of Meningococcal Vaccines  ................................ ...............  24 
1.3.7.  Vaccine against B Serogroup  ................................ ................................ .... 24 
1.3.8.  Vaccine against X Serogroup  ................................ ................................ .... 24 
1.4. Study Vaccine  ................................ ................................ ................................ .......24 
1.5. Summary of Nonclinical Studies  ................................ ................................ ......... 25 
1.5.1.  Non-Good Laboratory Practice (GLP) Nonclinical Pharmacology/Proof of 
Concept Studies  ................................ ................................ ........................  25 
1.5.2.  Toxicology Studies  ................................ ................................ ....................  26 
1.5.3.  Immunogenicity Studies  ................................ ................................ ............  27 
1.6. Clinical Studies  ................................ ................................ ................................ ....30 
2. HYPOTHESIS, SCIENTIF IC RATIONALE, OBJECT IVES AND STUDY DESIG N ..........  30 
2.1. Study Hypotheses  ................................ ................................ ................................ 30 
2.2. Scientific Rationale  ................................ ................................ .............................. 31 
2.3. Overall Clinical Development Strategy  ................................ ............................... 31 
2.4. Study Design  ................................ ................................ ................................ ........ 31 
2.4.1.  Discussion of Study Design  ................................ ................................ ....... 32 
2.4.2.  Primary Objective  ................................ ................................ ......................  32 
2.4.3.  Secondary Objective  ................................ ................................ .................  32 
2.4.4.  Primary Endpoints  ................................ ................................ .....................  32 
2.4.5.  Secondary Endpoints  ................................ ................................ ................  32 
2.4.6.  Exploratory Endpoints  ................................ ................................ ...............  33 
2.4.7.  Randomization and Vaccination  ................................ ................................  33 
3. STUDY PRODUCTS  ................................ ................................ ................................ ....... 33 
3.1. Test Vaccine (MCV -5) ................................ ................................ ........................... 33 
3.1.1.  Product Description  ................................ ................................ ...................  33 
3.1.2. Manufacturer  ................................ ................................ .............................  34 
3.1.3.  Presentation and Formulation  ................................ ................................ ... 34 
3.1.4.  Stability and Storage  ................................ ................................ .................  34 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 3 of 106 3.2. Diluents  ................................ ................................ ................................ ................. 34 
3.2.1.  Adjuvanted Diluent  ................................ ................................ ....................  34 
3.2.2.  Non-Adjuvanted Diluent  ................................ ................................ ............  35 
3.3. Reference Vaccine (Menactra®)26 ................................ ................................ ........ 35 
3.3.1.  Product Description  ................................ ................................ ...................  35 
3.3.2. Manufacturer  ................................ ................................ .............................  35 
3.3.3.  Presentation and Formulation  ................................ ................................ ... 35 
3.3.4.  Stability and Storage  ................................ ................................ .................  35 
3.4. Preparation and Administration  ................................ ................................ .......... 36 
3.4.1.  Adjuvanted MCV -5 ................................ ................................ ....................  36 
3.4.2.  Non-Adjuvanted MCV -5 ................................ ................................ ............  37 
3.4.3.  Menactra® ................................ ................................ ................................ . 37 
3.5. Accountability and Disposal  ................................ ................................ ............... 37 
4. STUDY POPULATION  ................................ ................................ ................................ .... 39 
4.1. Clinical Trial Site  ................................ ................................ ................................ ..39 
4.2. Study Population  ................................ ................................ ................................ ..39 
4.3. Eligibility  ................................ ................................ ................................ ............... 39 
4.3.1.  Inclu sion Criteria  ................................ ................................ .......................  39 
4.3.2.  Exclusion Criteria  ................................ ................................ ......................  40 
5. STUDY PROCEDURES  ................................ ................................ ................................ .. 41 
5.1. Recruitment  ................................ ................................ ................................ .......... 41 
5.2. Screening, Randomization, Masking Procedures, Study Visits  ........................ 41 
5.2.1.  Initial and Continuing Informed Consent  ................................ ....................  41 
5.2.2.  Screening, Visit 1 (Day -28 to -1) ................................ ...............................  42 
5.2.3.  Randomization  ................................ ................................ ..........................  42 
5.2.4.  Vaccination, Visit 2 (Day 1)  ................................ ................................ ....... 43 
5.2.5.  Visit 3 (Day 8 +3 days)  ................................ ................................ ..............  44 
5.2.6.  Visit 4 (Day 29 +14 days)  ................................ ................................ ..........  44 
5.2.7.  Visit 5 (Day 85 +14 days)  ................................ ................................ ..........  45 
5.2.8.  Final Study Contact (Day 180 ±21 days)  ................................ ...................  45 
5.3. Unscheduled Visits  ................................ ................................ .............................. 45 
5.4. Early Termination  ................................ ................................ ................................ .45 
5.5. Procedure Methods  ................................ ................................ .............................. 45 
5.5.1. Vital Signs  ................................ ................................ ................................ . 45 
5.5.2.  Height and Weight  ................................ ................................ .....................  46 
5.5.3.  Physical Examination  ................................ ................................ ................  46 
5.5.4.  Medical History  ................................ ................................ ..........................  46 
5.5.5.  Injection Site Examination  ................................ ................................ .........  46 
5.5.6.  Assessment of Reactogenicity  ................................ ................................ .. 46 
5.5.7.  Concomitant Therapy  ................................ ................................ ................  47 
5.5.8. Clinical Laboratory Testing  ................................ ................................ ........  47 
5.5.9.  Early Termination from Study  ................................ ................................ .... 47 
5.5.10.  Contraception and Pregnancy  ................................ ................................ ... 48 
6. LABORATORY EVALUATIO NS ................................ ................................ .....................  48 
6.1. Sample Collection, Distribution and Storage  ................................ ..................... 48 
6.2. Safety Clinical Laboratory Assays  ................................ ................................ ......48 
6.3. Immunological Assays  ................................ ................................ ........................ 48 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 4 of 106 6.4. Assay Qualification, Standardization and Validation  ................................ ........ 49 
6.5. Biohazard Containment  ................................ ................................ ....................... 49 
7. STATISTICAL DESIGN A ND ANALYSIS  ................................ ................................ ....... 49 
7.1. Overview and General Design  ................................ ................................ ............. 49 
7.2. Randomization and Blinding Procedures  ................................ ........................... 49 
7.3. Objectives and Endpoints  ................................ ................................ ................... 50 
7.3.1.  Primary  ................................ ................................ ................................ ...... 50 
7.3.2.  Secondary  ................................ ................................ ................................ . 50 
7.3.3.  Exploratory  ................................ ................................ ................................  51 
7.4. Sample Size Justification  ................................ ................................ .................... 51 
7.5. Analytical Methodology  ................................ ................................ ....................... 51 
7.5.1.  Analysis Population  ................................ ................................ ...................  51 
7.5.2.  Statistical Method  ................................ ................................ ......................  52 
8. SAFETY ASSESSMENT AN D REPORTING  ................................ ................................ .. 53 
8.1. Safety Events  ................................ ................................ ................................ ........ 53 
8.2. Reporting Period  ................................ ................................ ................................ ..54 
8.3. Definitions  ................................ ................................ ................................ ............ 54 
8.3.1.  Adverse Event (AE)  ................................ ................................ ...................  54 
8.3.2.  Serious Adverse Events (Defined as Serious Adverse Events, Serious 
Suspected Adverse Reactions or Serious Adverse Reactions) ..................  54 
8.3.3.  Unexpected Adverse Event  ................................ ................................ ....... 54 
8.4. Severity Grading  ................................ ................................ ................................ ..55 
8.5. Guidelines for Determining Causality of an Adverse Event  .............................. 55 
8.6. Assessment of Outcome of Adverse Event  ................................ ........................ 55 
8.7. Adverse Event Identification, Resolution and Reporting  ................................ ..55 
8.7.1.  AE Resolution  ................................ ................................ ...........................  57 
8.7.2.  General Recording and Reporting Procedures  ................................ ..........  57 
8.7.3.  SAE Recording and Reporting Procedures  ................................ ...............  57 
8.7.4.  Site Reporting of Events  ................................ ................................ ............  58 
8.8. Serious Adverse Event Notification  ................................ ................................ ....59 
8.8.1.  Notifications and Review  ................................ ................................ ...........  59 
8.8.2.  Expedited Reporting  ................................ ................................ ..................  59 
8.8.3.  Notifying the Safety Review Committee  ................................ .....................  60 
8.8.4.  Notifying the Institutional Review Board  ................................ ....................  60 
9. SAFETY MONITORING  ................................ ................................ ................................ .. 60 
9.1. Safety Review Committee  ................................ ................................ .................... 60 
9.2. Study Pause Rule  ................................ ................................ ................................ .61 
9.2.1.  Pause Procedure  ................................ ................................ ......................  61 
10. DATA MANAGEMENT  ................................ ................................ ................................ .... 62 
10.1.  Case Report Form Development and Completion  ................................ ............. 62 
10.2.  Details of Data Management  ................................ ................................ ................ 62 
10.2.1.  Coding ................................ ................................ ................................ ....... 62 
10.2.2.  Data Validation  ................................ ................................ ..........................  63 
10.2.3. Source Data Verification  ................................ ................................ ............  63 
10.2.4.  Definition of Source Data ................................ ................................ ...........  63 
10.2.5.  Definition of Source Document  ................................ ................................ .. 63 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 5 of 106 10.3.  Database Locking Procedures  ................................ ................................ ............ 63 
10.4.  Record Archival  ................................ ................................ ................................ ....63 
10.5.  Screen Failures  ................................ ................................ ................................ ....64 
10.6.  Protocol Deviations  ................................ ................................ .............................. 64 
11. STUDY MONITORING  ................................ ................................ ................................ .... 64 
11.1.  Independent Auditing  ................................ ................................ .......................... 65 
11.2.  Regulatory Agency Auditing  ................................ ................................ ............... 65 
12. OBLIGATIONS AND ROLE S OF THE SPONSOR, PI  AND STUDY PERSONNEL  ........  65 
13. ETHICAL CONSIDERATIO NS AND  INFORMED CONSENT  ................................ .........  66 
13.1.  Informed Consent Process  ................................ ................................ .................. 66 
13.2.  Risk/Benefit  ................................ ................................ ................................ .......... 66 
13.3.  Protocol Review Process  ................................ ................................ ..................... 67 
13.4.  Participant Confidentiality  ................................ ................................ ................... 68 
13.5.  Reimbursement  ................................ ................................ ................................ ....68 
13.6.  Storage of Specimens  ................................ ................................ .......................... 68 
14. APPENDICES  ................................ ................................ ................................ .................  69 
14.1.  APPENDIX I: Schedule of Events  ................................ ................................ ........ 69 
14.2.  APPENDIX II: Toxicity Grading Scale  ................................ ................................ ..70 
14.3.  APPENDIX III: References  ................................ ................................ ..................  104 
 
 
 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 6 of 106 LIST  OF ABBREVIATIONS AN D ACRONYMS  
 
ABBREVIATION  
/ ACRONYM  DEFINITION  
µg or mcg  Microgram  
4-PP  4-Pyrrolidinopyridine  
AE  adverse event  
Alum  Aluminum phosphate  
CDC  Centers for Disease Control  
CI Confidence interval  
cm Centimeter  
CMV  conjugated meningococcal  vaccines  
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments on Animals  
CPPT  1-cyano -4 pyrrolidinopyridinium tetrafluoroborate  
CRF Case report form  
CRM  cross reactive material  
CRO  Contract research organization  
CVD  Centre for Vaccine Development  
DAIDS  Division of AIDS  
DSMB  Data Safety Monitoring Board  
ELISA  Enzyme linked immunosorbent assay  
FDA  Food and Drug Administration (US)  
FIH  first in human  
GCP  Good Clinical Practices  
GLP  Good Laboratory Practices  
GMTs  geometric mean titers  
HBV Hepatitis B virus  
HCV  Hepatitis C virus  
HIV Human immunodeficiency virus  
ICD Informed consent document  
ICF Informed consent form  
Ig Immunoglobulin  
IM  Intramuscular  
IMD invasive meningococcal disease  
INDA  Investigational New Drug Application  
IRB Institutional review board  
kg Kilogram  
mL Milliliter  
MedDRA  Medical Dictionary for Regulatory Activities  
NIBSC  National Institute for Biological Standards and Control  
NMT  Not more than  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 7 of 106 ABBREVIATION  
/ ACRONYM  DEFINITION  
PCR  Polymerase chain reaction  
PHE Public Health England  
PI Principal Investigator  
PS  Polysaccharide  
PT Preferred term  
q.s. Quantum satis  
rSBA  rabbit complement serum bactericidal activity  
SAE  serious adverse event  
SBA  serum bactericidal activity  
SIIPL  Serum Institute of India Private Limited.  
SOC  System organ class  
SOP  Standard Operating Procedure  
SRC  Safety Review Committee  
TCMV  Tetravalent conjugate meningococcal vaccines  
TT  tetanus toxoid  
UK United Kingdom  
UMB  University of Maryland, Baltimore  
USA  United States of America  
w/v Weight by volume  
WHO  World Health Organization  
 
 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 8 of 106 PROTOCOL SIGNATURE P AGE  
 
 
PATH , the study Sponsor, will keep a list of Investigator(s), who must provide a Curriculum Vita  
(CV) and a copy of their medical licenses to the Sponsor or Sponsor representatives. The Sponsor 
will keep a list and qualification records of all relevant Sponsor study personnel.  
 
The Emmes  Corporation will conduct site monitoring and provide medical mo nitoring, data 
management, statistical analysis, quality assurance , safety and pharmacovigilance services.  
 
Site Contact  Phone Number  Email Address  
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD  
Wilbur H. Chen, MD, MS  
(Principal Investigator)  410-706-1188  wchen@medicine.umaryland.edu  
Kathleen M. Neuzil, MD, MPH  410-706-5328  kneuzil@medicine.umaryland.edu  
James D. Campbell, MD, MS  410-706-7284  jcampbel@medicine.umaryland.edu  
 
 
SIGNATURE OF SITE Principal Investigator ( PI):  
 
“I have read the foregoing protocol and agree to conduct the study as outlined herein.”  
 
 
 
_____________________________________   ____________________  
Principal Investigator      DD/MM/YY  
 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 9 of 106 PARTICIPATING INSTIT UTIONS  
Sponsor  PATH  
2201  Westlake Avenue, Suite 200  
Seattle, WA 98121 USA  
Clinical Trial Site  Center  for Vaccine Development  
University of Maryland  
685 West Baltimore Street, Room 480  
Baltimore, MD 21201 -1509  USA 
Phone:  410-706-5328  
Fax: 410-706-6205  
Research Laboratory  Vaccine Evaluation Unit, Public Health England (PHE), 
Manchester, U nited Kingdom  
Collaborating Partner  & Vaccine 
Manufacturer  Serum Institute of India Private Limited (SIIPL) 
212/2 Hadapsaar, Pune – 411028, India  
Phone: +91 206 993 900 ext. 2384  
Fax: +91  206 993 945  
Site Monitoring  The Emmes Corporation  
401 N. Washington St., Suite 700  
Rockville, MD  20850  
USA 
Medical Monitoring  The Emmes Corporation  
401 N. Washington St., Suite 700  
Rockville, MD  20850  
USA 
Data Center and  
Statistical Support  The Emmes Corporation  
401 N. Washington St., Suite 700  
Rockville, MD  20850  
USA 
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 10 of 106 STUDY SYNOPSIS  
TITLE  
A Phase 1, double blind, randomized, controlled study to evaluate the safety and 
immunogenicity of a new Meningococcal Conjugate Vaccine containing serogroups A ,C,Y,W 
and X in healthy adults  
NAME OF THE STUDY VA CCINE  
Meningococcal (A, C, Y, W, X) Polysaccharide Conjugated Vaccine (freeze -dried), also 
referred to as MCV -5 
STUDY NUMBER  
ACYWX -001/ VAC -046 
PROJECT PHASE  
Phase 1 
SPONSOR  
PATH  
COLLABORATING PARTNER  AND VACCINE MANUFACTURER  
Serum Institute of India Private Limited (SII PL) 
PRINCIPAL INVESTIGATOR  
Dr. Wilbur H. Chen, MD, MS  
Chief, Adult Clinical Studies section  
Center for Vaccine Development  
University of Maryland School of Medicine  
685 W. Baltimore St reet, Suite 480  
Baltimore, MD 21201  
Tel: 410 -706-1188  
Fax: 410 -706-6205  
Email: wchen@medicine.umaryland.edu  
SPONSOR MEDICAL OFFICER  
Dr. Igor Smolenov, MD  
Vaccine Development Global Program – PATH  
2201 Westlake Ave #200  
Seattle, WA 98121, USA  
Email: ismolenov@path.org  
VACCINE MA NUFACTURER MEDICAL EXPERT  
Dr. Prasad Kulkarni, MD  
Medical Director,  
Serum Institute of India  Private  Ltd. Pune  
Tel: 91 -20-26602384  
Fax: 91 -20-26993945  
Email: drpsk@seruminstitute.com  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 11 of 106 VACCINE MANUFACTURER MEDICAL OFFICER  
Dr. Amol Chaudhari, MD  
Senior Manager (Clinical Trials & Pharmacovigilance)  
Serum Institute of India  Private  Ltd. Pune  
Tel: 91 -20-26602869  
Fax: 91 -20-26993945  
Email:amol.chaudhari@seruminstitute.com  
EMMES  MEDICAL MONITOR  
Robert Lindblad, MD  
The Emmes Corporation  
401 N. Washington St., Suite 700  
Rockville, MD  20850  
PATH CLINICAL OPERATIONS MANAGER  
Lionel Martellet  
207 Rte de Ferney, Geneva, 1218 Switzerland   
Office: +41 22 747 1055 / Mobile: +33 699 872 551  
Email: lmartellet@path.org  
CONTRACT RESEARCH ORGANIZATION  
The Emmes Corporation  
401 N. Washington St., Suite 700  
Rockville, MD  20850  
RESEARCH LABORATOR Y 
Vaccine Evaluation Unit,  Public Health England (PHE), Manchester , United Kingdom  
INVESTIGATIONAL PHARMACY  
University of Maryland Medical Center  
Investigational Drug Service (IDS) Pharmacy  
22 South Greene Street  
Room N9E14  
Baltimore, MD 21201  
Prashant Patel, PharmD  
Manager, IDS Pharmacy  
Tel: 410 -328-5468/5160  
Fax: 410 -328-7326  
Email: ppatel13@umm.edu  
 
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 12 of 106 STUDY OBJECTIVES  
 
Primary Objective:  
To evaluate the safety of adjuvanted and non -adjuvanted formulations of MCV -5 vaccine.  
Secondary Objectives:  
To assess the immune response of adjuvanted and non -adjuvanted formulations of MCV -5 
vaccine.  
STUDY ENDPOINTS  
 
Primary Endpoints  
 
1. The occurrence and severity of  solicited local and systemic post immunization reactions 
within seven  days following vaccination . 
2. The occurrence, severity, and relatedness to vaccination of  unsolicited adverse events  
(AE) for 28 days following vaccination, and serious adverse events  (SAE)  for 6 months 
following vaccination.  
 
Secondary Endpoints  
 
1. The percentage of participant s who show a seroconversion for Meningococcal 
Polysaccharide A, C, Y, W , and X specific antibodies, i.e. a ≥4-fold increase in post-
immunization rabbit complement serum bactericidal activity ( rSBA ) titer with respect to 
pre-immunization rSBA titer, at 28 days after a single vaccine dose.  
2. The percentage of participant s who show a post -immunization seroprotection titer for 
Meningococcal Polysacchari de A, C, Y, W and X specific antibodies defined as rSBA 
titer of 1:8 and 1:128 at 28 days after a single vaccine dose . 
3. Geometric mean titers (GMTs) of Meningococcal Polysaccharide A, C, Y, W , and X 
specific antibodies at 28 days after a single vaccine dose , as measured by rSBA assay . 
STUDY HYPOTHES ES 
Primary hypothesis: Two formulations (adjuvanted and non -adjuvanted) of  MCV -5 vaccine 
when given to healthy adults will be safe and well tolerated.  
Secondary hypothesis: Two formulations (adjuvanted and non -adjuvanted) of  MCV -5 vaccine 
when given to healthy adults will induce immune response to all the five serogroups of the 
vaccines.  
STUD Y DESIGN  
This is a Phase 1, single center, double -blind, randomized, controlled clinical trial to be 
performed in 18  to 45 year old healthy volunteers.  
The study will have three arms with three vaccines given in a 1:1:1 ratio: adjuvanted MCV -5, 
non-adjuvanted MCV -5 and Menactra®.  
Each participant will receive a single intramuscular  (IM) injection of one of the three vacci nes 
and will be followed up for six months after the vaccination.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 13 of 106 Safety evaluation will include safety laboratory parameters at baseline and seven  days after 
vaccination, local and systemic post -immunization reactions for seven  days after vaccination. 
Adverse events for one month after vaccination and serious adverse events for the entire study 
period ( six months) will be collected.  
The vaccinator will be aware of treatment allocation, although he/she will neither be able to 
influence or decide this allocation nor be part of the safety assessment. The study team involved 
in assessment of safety outcome as well as participants will be unaware of the group allocation.  
STUDY RATIONALE  
Currently, three polyvalent conjugate vaccines are available to protect against meningococcal 
disease. All three are tetravalent (serogroups A, C, W , and Y) vaccines; Menactra® (Sanofi 
Pasteur Inc.),  Menveo® (Novartis) and Nimenrix® (GlaxoSmithKline Biologicals). There is vast 
experience with the use of these vaccines,  which are generally well tolerated in all age groups. 
At this time,there is no licenced vaccine giving protection against meningococcal serogroup X 
which has caused many outbreaks in Africa and Europe in the recent past.  
 
Following the MenAfriVac® MenA m onovalent conjugate vaccine development experience, 
SIIPL has developed a candidate polyvalent conjugate vaccine composed of serogroups A, C, 
Y, W , and X  Neisseria meningitidis  capsular polysaccharides. The individual polysaccharides 
are conjugated to protein carriers, cross reactive material ( CRM ) or tetanus toxoid  (TT), and 
formulated with or without aluminum  phosphate (alum) as an adjuvant. The vaccine is intended 
for the prevention of meningitis and/or septicemia caused by serogroups A , C, Y, W , and X 
N. meningitidis in countries where the disease is endemic and causes large epidemics such as 
the countries in the African meningitis belt. The target population consists of infants, children 
and adults covering an age group of 9 months to 55 years.  
 
This first -in-human  (FIH) Phase 1 clinical study is designed to evaluate primarily the safety of 
the study vaccine. The three -group design will allow safety evaluation of the adjuvanted and 
non-adjuvanted MCV -5 formulations. The quadrivalent (ACYW) Menactra® vaccine has been 
chosen as a control vaccine comparator given the large safety database accumulated since the 
vaccine was  introduced in the US in 2005, prequalified by World Health Organization ( WHO ) 
and pro gressively introduced in other countries.  
The secondary objective of the study is immuno logic evaluations of both adjuvanted and 
non-adjuvanted vaccine formulations.  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 14 of 106 STUDY VACCINES  
MCV -5: 
Two formulations (adjuvanted and non -adjuvanted) of the MCV -5 meningococcal conjugate 
vaccine will be  used in the study. MCV -5 will be available as lyophilized product in a five dose 
vial containing meningococcal A and X polysaccharides conjugated to tetanus toxoid and 
meningococcal C, Y , and W polysaccharides conju gated to CRM.   
The vaccine will be reconstituted with either normal saline  (non-adjuvanted) or saline containing 
aluminum phosphate at 125 µg Al3+ /dose (adjuvanted) just prior to administration.  
Composition of reconstituted final solution of one single 0. 5 mL 
dose of adjuvanted MCV -5 vaccine  
Vaccine component  Per 0.5 mL dose  
Meningococcal A polysaccharide*  5 g 
Meningococcal C polysaccharide# 5 g 
Meningococcal Y polysaccharide# 5 g 
Meningococcal W polysaccharide# 5 g 
Meningococcal X  polysaccharide*  5 g 
Sucrose  2.42 mg  
Sodium Citrate  0.40 mg  
Tris (Trometomol ) 0.098 mg  
Al3+adjuvant  125 g /dose  
0.9% Sodium Chloride  q. s.  
Tetanus Toxoid  7.8 to 33.4 µg . 
CRM  11.7 to 50.1 µg  
* - Each c onjugated to Tetanus Toxoid ( TT);  
# - Each c onjugated to  CRM , 
q.s. - Quantum satis  
 
Composition of reconstituted final solution of one single 0.5 m L  
dose of non -adjuvanted MCV -5 vaccine  
Vaccine component  Per 0.5 mL dose  
Meningococcal A polysaccharide*  5 g 
Meningococcal C polysaccharide# 5 g 
Meningococcal Y  polysaccharide# 5 g 
Meningococcal W polysaccharide# 5 g 
Meningococcal X  polysaccharide*  5 g 
Sucrose  2.42 mg  
Sodium Citrate  0.40 mg  
Tris (Trometomol ) 0.098 mg  
0.9% Sodium Chloride  q. s.  
Tetanus Toxoid  7.8 to 33.4 µg  
CRM  11.7 to 50.1 µg  
* - Each c onjugated to Tetanus Toxoid (TT); 
#- Each c onjugated to CRM , 
 q.s. - Quantum satis  
 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 15 of 106 Menactra®: 
Menactra® is a sterile, clear to slightly turbid liquid and each 0.5 mL dose is formulated in sodium 
phosphate buffered isotonic sodium chloride solution to contain four mcg each of 
meningococcal A, C, Y , and W polysaccharides conjugated to approximately 48 mcg of 
diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 mcg 
(0.000532%), by calculation.   
STUDY PROCEDURES & VISIT SCHEDULE  
After volunteers have signed the written informed consent, they will be screened for eligibility 
into the study. Screening will take place within 28 days prior to vaccination (Visit 1; Screening). 
A blood sample (up to 18 mL) will be taken at the screening  visit for laboratory testing.  
The following assessments will be conducted during the screening visit: medical history, 
physical examination, vital signs measurement and laboratory evaluation including hematology, 
serum chemistry and viral serology  for Hum an immunodeficiency virus (HIV), Hepatitis B virus 
(HBV), and Hepatitis C virus ( HCV). A test for pregnancy will be performed among females of 
child bearing potential. Inclusion/exclusion criteria will be assessed for eligibility.  
At Visit 2 (Vaccination),  eligible volunteers will be randomized in a 1:1:1 ratio to either one of 
the following groups:  
Group  Vaccine  
1 (n=20)  Adjuvanted Study vaccine ( MCV -5) 
2 (n=20)  Non-adjuvanted Study vaccine ( MCV -5) 
3 (n=20)  Reference vaccine ( Menactra®, ACYW)  
 
Baseline  blood sample ( 20 mL) for immunogenicity testing will be collected before 
randomization on the day of vaccination and thereafter vaccine will be given as a single 
intramuscular injection of 0.5 mL in the deltoid. The day of vaccination will be considered as 
Day 1. After vaccination, participants will be observed for 60 minutes a t the clinic to detect any 
immediate reactions or any other AE. All relevant information will be reported in the Case Report 
Form (CRF). A Memory Aid will be distributed and participants will be instructed to record post -
immunization reactions, adverse eve nts and concomitant medications. Participants  will be 
informed to return to study centre  for Visit 3 (Day 8).  
At Visit 3 (Day 8), participants will undergo a targeted physical examination,  vital sign 
measurement  and a blood sample will be collected (up to  8 mL) to repeat the safety laboratory 
evaluations. Memory Aid records will be discussed with the participants, if needed, reconciled 
by the investigator/designee  before recording in source document  and transcribed into the CRF.  
At Visit 4 (Day 29), the participants will undergo a targeted physical examin ation , vital sign 
measure ment  and review of  interim health history, medication use and any report of adverse 
event  through personal interview . A blood sample ( 30 mL) will be collected for immunogen icity 
evaluations. All the relevant information will be recorded into the CRF. The participant will be 
informed of the Visit 5 schedule .  
At Visit 5  (85 days after vaccination), the participants will undergo targeted physical examination 
and review of interim medical history including medication use. All serious adverse events will 
be recorded into the CRF by the investigator/designee.  
At Final study contact (180 ± 21 days after vaccination), the participant will be contacted by 
telephone to assess any serious adverse events that may have occurred.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 16 of 106 STUDY DURATION  
Participants will be followed for approximately six months after  vaccination . 
STUDY POPULATION  
60 healthy male and female adult participants aged 18  to 45 years of age .  
SAFETY ASSESSMENTS  
Safety will be assessed during the study via  the following parameters:  
- Solicited local and systemic reactions for 7 days post -vaccination . 
- Adverse events will be recorded for 28 days post vaccination . 
- SAEs will be recorded for the study period of 180 days . 
SAFETY MONITORING : 
A Safety Review Committee (SRC) comprised of the Principal Investigator ( PI), a medical 
expert with experience in vaccine pharmacovigilance not involved with the study , the Emmes 
medical monitor, Sponsor medical officer and SIIPL medical expert will be established to 
monitor participant safety throughout the duration of the study. The Emmes  study statistician, 
with assistance of the data management staff, will prepare safety reports as needed for SRC 
discussions.  
 
During the vacc ination period , the SRC will review weekly the safety data. At any time during 
the study, the E mmes  Coordinating Center  will notify the SRC of a d hoc review if pause criteria 
may have been met.  
 
The SRC reviews will be summarized with consensus recommendations to the study Sponsor 
as to whether there are safety concerns and whether the study should continue without change, 
be modified, paused or stopped. The SRC may request review of unblinded safety data by the 
vaccine pharmacovigilance expert  in its deliberation. SRC consensus r ecommendations 
regarding modifying or stopping further enrolment  may involve Sponsor consultation with the 
local regulatory authorities.  
 
If at any time, a decision is made to discontinue administration of study product to all volunteers, 
expeditious notification will be provided by the sponsor to the US Food and Drug Administration 
(FDA), and  by the PI to the  University of Maryland, Baltimo re (UMB)  Institutional Review Board 
(IRB). 
The following study pause rules will automatically pause or halt further vaccinations. However , 
volunteers already enrolled will continued to be followed for safety during the pause. These 
pause rules refer to suspected adverse reactions and will be triggered automatically if any of 
the event described below are met during the conduct of the study:  
• One or more participants experience a serious adverse reaction . 
• One or more participants experience a grade four injection site reaction . 
• Two or more participants experience the same grade three  injection site reaction .  
• Two or more participants  with the same severe (grade three ) systemic reactogenicity 
signs or symptoms, within seven days following injection . 
• Two or more participants experience the same vaccine -related grade three  or higher 
clinical (including fever) or laboratory abnormality.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 17 of 106 STATISTICAL CONSIDERATION:  
 
Since this study is a Phase 1 trial, the sample size is designed to provide preliminary safety 
and immunogenicity data that may support testing the study product in larger adult cohorts or 
in age -descending studies.  
 
With 20 vaccine recipients per group, this study ’s design  allow s a greater than 90% chance of 
observing an AE that has an 11% chance of occurrence. Conversely, if no AEs are observed 
in 20 vaccine recipients, the study will be able to rule out AEs occurring at a r ate of 
approximately 14% based on the upper bounds of the one -sided 95% Confidence Interval (CI).  
 
 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 18 of 106 1. BACKGROUND AND INTRO DUCTION  
1.1. Pathogen  
Among several different bacteria that can cause meningitis, Neisseria meningitidis  (a gram -
negative aerobic capsular bacterium, also referred as meningococcus) , is known to cause large 
epidemics. Neisseria meningitidis  otherwise a harmless commensal of human nasopharynx, 
under appropriate conditions is responsible for invasive meningoco ccal disease (IMD) –a 
spectrum of diseases that includes most commonly meningitis and  fulminant septicaemia. 
Pneumonia, myocarditis, or pericarditis may also occur in IMD, albeit less commonly.1, 2 
Once acquired, meningoccocci colonize the nasopharynx and patient may develop between the 
spectrum of an asymptomatic carrier state to a full blo wn IMD.1 
Meningocci are classified into serogroups based on their capsular polysaccharides. Six  of these 
serougroups viz. A, B, C, W, X , and Y are known to cause majority of IMD cases.2 
These serogroups have the potential to cause large epidemics but this potential varies in each 
serogroup with re spect to time and geographic location.3 Serogroup A for example has been the 
most important cause of meningitis in sub -Saharan Africa and its outbreaks are commonest 
during December to June. On  the other hand majority of IMD cases in Europe and USA are 
caused most commonly by serogroup B, follo wed by C and Y  (Figure 1). Most recently cases of 
serogroup X are on the rise especially in Africa.2, 4 
 
Figure 1 : Global serogroup distribution of invasive meningococcal disease .2 
1.2. Burden of Disease  
Apart from serogroup  variability , IMD also shows variation with respect to age groups with peak 
incidence occuring among children less than 2 years of age and adolescents between 16  and 
21 years. During epidemics, disease rates show a shift towards older age groups.2 

Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 19 of 106 Meningococcal disease commonly alternates between an endemic situation of few isolated cases 
and fatal unpredictab le epidemics in  the African meningitis belt  (a large area that spans 
sub-Saharan Africa from Senegal in the west to Ethiopia in the east ).5 This region has the highest 
annual incidence of IMD and is plagued w ith problem of recuring epidemics of large proportions. 
The incidence has been known to reach rates of up to 1000 cases per 100,000 people or 1% of 
the entire population.3 This was seen during the large epidemics of 1996 and 2000  through 2001. 
In 1996  and 19 97 there were  > 250,000 cases, an estimated 25,000 deaths, and disability in 
50,000 people. It is believed to be the largest epidemic in history. Similarly in the 2006  to 2007 
epidemic season, there were 53,438 suspected cases and 3 ,816 deaths were reported to WHO 
from 15 African countries.4 
Outside of the African meningitis belt, the incidence of IMD is significantly low, although there 
have been reports of outbreaks. In such areas any substantial increase in IMD cases above that 
which is expected at that place and time is considered as outbreak.3, 4 
Respiratory droplets are  the main source of m eningococcal transmission and occurs most 
commonly due to close contacts with asymptomatic carrier.6 Symptoms of IMD mainly include  
fever, los s of appetite, lethargy, vomiting, diarrhoea, photophobia and convulsions , and usually 
manifest 1  to 14 days after acquiring the pathogen .1 
Meningococcal meningitis and fulminant septicemia —the two most serious presentations of 
IMD—may prove fatal in 50% of cases if untreated within 24  to 48 hours. Even when adequately 
treated, the mortality is close to 10%. Among the survivors of meningitis, it may cause in 10  to 
20% of cases, severe permanent brain damage and sequelae such as mental retardation, 
deafness, epilepsy, or other neurological disorders.2, 4 
1.3. Meningococcal Vaccines  
The increasing resitance to antibiotics and associated escalation in healthcares costs makes 
vaccination as the best strategy to tackle invasive meningococcal disease.2, 7 
1.3.1.  Polysaccharide Vaccines  
As depicted in Figure 2, the earliest vaccines against meningococci were discovered in the 1970s. 
The first ever meningococcal vaccine was developed against serogroup C as a response to 
recurring epidemics among mili tary recruits in the USA. Eventually, further research led to 
availibility of vaccines against serogroups A, W, and Y. These were purified bacterial 
polysaccharide vaccines or “plain” polysaccharide vaccines that lacked conjugation.8, 9 
Polysaccharide vaccines have an excellent safety profile and they have more than served their 
purpose of controlling outbreaks in military and other similar confi ned set ups. Later these 
vaccines were also used in endemic regions for prophylaxis.2 Subsequently it was noted that the 
polysaccharide vaccines also showed good efficacy (> 85%) in older children and  adults, 
however, they produced variable respo nse among younger children (below 24 months of age) 
and often failed to provide protection in this population.2, 8 
 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 20 of 106  
Figure 2 : Timeline of meningococcal vaccine development.8 OMV, outer membrane vesicle .  
* Two serogroup B vaccines were approved in USA in late 2014 and early 2015.  
Further, polysaccharide vaccines do not provide long term protection or immune memory. Instead 
they may induce immune hyporesponsiveness, particularly for serogroup C, on repeated 
administration. This is because of lack of T -cell induction by these vaccine s, as a result of which 
the protection lasts for no more than three  to five years post -vaccination .7, 8 These vaccines also 
lack the ability to prevent organis m transmission as they have no effect on pharyngeal carriage 
and do not confer herd immunity.10-12 
Today, polysaccharide vaccines are licensed as bivalent (serogroups A and C), trivalent 
(serogroups A, C, and W -135), or quadravalent (serogroups A, C, Y, and W -135), although their 
availibility is very limited in most countries.2 The drawbacks listed above made polysaccharide 
meningococcal vaccines unsuitable for use in population -scale interventions outside of epidemics 
and for infant immunization.9 They are recommended in developed world for use in outbreaks 
related to specific strains, and as prophylaxis in susceptible travellers above 55 years of age as 
well as for military recruits.13 
1.3.2.  Conjugate Vaccines  
The problems associated with the use of polysaccharide vaccines were overcome by the process 
of conjugation, wherein the capsular polysaccharide is conjugated to a highly  immunogenic T -cell 
stimulating antigens such as CRM, diphtheria or tetanus toxoids. V accine against serogroup C 
was the first conjugated vaccine against meningococcal disease , that was developed in the 1990s 
in the United Kingdom.9 
With their widespread use thereafter, conjugated mening ococcal vaccine s (CMV) proved superior 
to polysaccharide vaccines in eliciting T -cell responses and, thus, protected children less than 

Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 21 of 106 two years of age and induced immunologic memory. The advantage of immunologic memory is a 
booster response to subsequent doses of conjugate vaccines, a phenomena seen in all age 
groups. These vaccines also induce higher levels of protective titers and confer long-lasting 
protection. CMVs were also shown to overcome the problem of nasopharyngeal colonization and 
provide herd immunity. Furthermore, CMVs have not shown any hyporesponsiveness after 
repeated doses.10, 11 
Currently, monovalent (A or C), and tetravalent (A, C, W -135 and Y) conjugate meningococcal 
vaccines are available to protect against IMD.  
1.3.3.  Monovalent Conjugated V accine against Meningococcal Serogroup C 
(MenCCV)  
The monovalent vaccine  against C serogrouop contains polysaccharide conjugated to the carrier 
diphtheria toxoid, CRM, or tetanus toxoid without preservatives. It is licensed for children aged > 
two months, adolescents and adults. Infants aged two to eleven  months are given two doses (0.5 
mL per dose) with at least two months between the doses, followed by a booster dose about one 
year later .4 
The introduction of MenCCV in the routine infant immunization and a school -based “catch -up” in 
individuals up to 18 years of age in the United Kingdom (UK)  resulte d in reduction of 86.7% in the 
incidence of serogroup C within two years from 1999 to 2001. Number of  associated deaths also 
fell from 67 in 1999 to 5 in 2001, thanks to MenCCV.14 This prompted many other countries to 
introduce MenCCV in their immunization schedule with similar succes in controlling the sergroup 
C disease incidence.9 
1.3.4.  Monovalent Conjugated Vaccine against Meningococcal Serogroup A 
(MenA friVac®) 
The m ajority of the meningococcal epidemics in the African me ningitis belt over the years  have 
been caused by serogroup A with incidence rates as high as 500  cases  per 100,000  population. 
In an effort to overcome this problem in a cost -effective way, the Meningitis Vaccine Project 
(MVP), a partnership between the WH O and PATH, was established with funding from the Bill 
and Melinda Gates Foundation .15 The resultant product was a  monovalent vaccine against A 
serotype  called MenAfriVac® manufactured by Serum Institute of India  Private Limited , and 
developed  specifically to tackle the MenA epidemics in African Meningtis belt.10 
MenAfriVac® is a lyophilized vaccine containing purified meningococcal A polysaccharide 
conjugated to tetanus toxoid.2 The vaccine underwent an elaborate clinical development process 
that included a Phase 1 study in India, followed by seven  Phase 2 and 3 studies conducted in 
India and  the African meningitis belt.16, 17 
The Phase 1 clinical study was conducted among 74 Indian adults (24 received MenAfri Vac®, 25 
a meningecoccal  polysaccharide A and C vaccine, and 25 a tetanus toxoid vaccine) which 
involved a total of 48 weeks follow up for safety evaluation and four blood draws for testing 
immunogenicity (pre -immunization, and at 4 weeks, 24 weeks and 48 weeks post immunization). 
In the three v accine groups, solicited reactions were mild and transient and resolved without 
sequelae with commonest being pain, redness, and swelling. All other adverse events resolved 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 22 of 106 without sequelae and were unrelated to the vaccines. Four weeks after vaccination 8 3% of 
subjects in MenAfriVac® group had a ≥ 4 -fold increase in rSBA titers, 72% in the A/C group, and 
12% in the tetanus toxoid only vaccine group. rSBA GMTs and group A specific IgG Enzyme 
linked immunosorbent assay ( ELISA ) geometric mean concentrations ( GMCs ) were also higher 
in MenAfri Vac® groups as compared to A/C vaccine group (8,192 vs . 5,257 & 110 v s. 44 
respectivley). Furthermore all subjects in the MenAfriVac® group who had initial four -fold increase 
in rSBA titers four weeks after vaccination rema ined four-fold responders  one year later  thus 
showing persisten ce in antibody response. In summary the vaccine was found to be safe and 
immunogenic.18 
One of the Phase 2 clinical trials conducted among 12  to 23 month olds in Africa enrolled 601 
subjects to receive either MenAfri Vac® (n = 201), polysaccharide ACW Y (Mencevax®) vaccine (n 
= 200) or Haemophilus inlluenza  type b tetanus toxoid  conjugated ( Hib-TT) control vaccine (n = 
200). There was no immediate safety issue at week four post-primary immunization, with all the 
local reactions reported being transient and resolved without sequelae. More indurations were 
reported in the MenAfriVac® group vs. the Mencevax® group (p = 0.01). Rates of other adverse 
events were similar between vaccine groups and they were  unrelated to the study vaccines. Four 
weeks after vaccination 96% of subjects in the MenAfriVac® group had a ≥ 4-fold increase in Men 
A rSBA titer, 64% in the Mencevax® group and 36% in the Hib -TT vaccine group, whereas GMTs 
(rSBA) were 16 times greater after MenAfriVac® when compared with Mencevax® vaccine 
recipients. All but one subject in the  MenAfriVac® group  had a ≥ 4 -fold increase in ELISA IgG 
concentrations, as compa red to 78% in the Mencevax® group, and 4% in the Hib -TT group. 
Overall, the study MenAfriVac® showed  antibody responses that are not inferior to those achieved 
by the Mencevax® vaccine .  
Some of  the subjects  in this Phase 2 study  were further followed up for 40 weeks, and 82% 
subjects in the MenAfriVac group still showed a ≥ 4 -fold increase in rSBA titer vs. 38% in each of 
the other two groups. rSBA GMTs and ELISA GMCs were also higher in the Men AfriVac® group 
than the  other two groups. MenAfriVac® group also had higher number of subjects with Men A 
rSBA titers ≥ 1:128 and 4 -fold increase in ELISA specific IgG concentrations at 40 weeks. It was 
also found that the  MenAfriVac® induced immunological  memory since the subjects receiving 
booster at 40 weeks with either MenAfriVac® or polysaccharide vaccine showed highr GMTs 
(rSBA) if they were previously immunized with MenAfriVac®.  
MenAfriVac® vaccine was thus found to be safe and it showed the charact eristics of a conjugate 
vaccine with superior immunogenicity, effective inducement of immunological memory and 
inducement of bactericidal antibodies persisting at sustained levels after a single vaccine dose.15 
Another Phase 2/3, among 900 healthy children and adults was conducted in Mali, The Gambia 
and Senegal to compare safety and immunogenicity of MenAfriVac® (n = 604) with that of 
Mencevax® vaccine (n = 296). Age of subjects at mmunization was 2  to 10 years (n = 302), 11  to 
17 years (n = 301) and 18  to 29 years (n = 297). Safet y evaluation at four weeks did not show 
any SAEs or deaths. Local and systemic reactions, AEs and SAEs were similar between vaccine 
groups overall as well as within each age group.  Majority of the reactions were of mild or moderate 
intensity, transient and  resolved without sequelae. During an additional one -year follow up, a total 
of five SAEs were reported and  they were unrelated to study vaccines. A ≥ 4 -fold increase in rSBA 
titer at four weeks post -immunization was seen in 78% in MenAfriVac® group vs. 46 % in the 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 23 of 106 Mencevax® group. This remained consistent within each of the three age sub -groups. Even over 
a one year follow up MenAfriVac® group had a significantly higher sustained MenA antibody 
persistence. 15 
Another trial comparing the immunogenicity and safety of a single  dose MenAfriVac® against the 
meningococcal group A component of polysaccharide vaccine (Mencevax®) at 28 days was 
conducted among 340 Indian children (169 in MenAfri Vac® group) aged 2  to 10 years. Results 
showed 95.2% of children in MenAfriVac® group had a ≥4-fold response in rSBA as compared to 
78.2% in the Mencevax® group. Almost all children in both vaccine groups had a ≥4 -fold response 
in group A -specific IgG concentration but the IgG GMC was significantly greater in the 
MenAfriVac® group. Local and systemic reactions during the four days after immunization were 
similar for both vaccine groups except for tenderness (30.2% in  MenAfriVac® group vs . 12.3% in 
Mencevax® group). None of the adverse events or serious adverse events w ere related to the 
study vaccines.19 
The vaccine was subsequently licensed  in 2009 and was prequl aified by WHO in 2010 . Since 
then it has been widely used in over 217 million individuals of 1  to 29 years of age and has been 
found to be highly effective and safe.3, 20 -23 
Use of MenAfriVac® has been highly effective at preventing IMD of serogroup A, reducing it by 
nearly 100%, eliminating outbreaks as well as decreasing carrier sta tes.20, 24 It also reduced  the 
incidence in those too young or too old to have been vaccinated, demonstrating an additional 
indirect herd effect. In the data generated for two year s sin ce its use started in three African 
countries viz. Burkina Faso, Mali and Niger, there have been no cases of MenA disease reported  
in vaccinated population .10 
1.3.5.  Tetravalent Conjugate Meningococcal Vaccines (TCMV)  
Today, three different brands of TCMV are available viz. Menactra® (Sanofi), Menveo® (Novartis) 
and Nimenrix®  (Glaxo SmithKline Beecham) with each brand having serogroups A, C, W, an Y 
but conjugated to differen t proteins.2, 25 -27 
Menactra®, first ever TCMV uses diphtheria toxoid as conjugate, whereas Menveo® and Nimnerix® 
use CRM and Tetanus Toxoid respectively for conjugation of p olysaccharides. Menact ra®, 
Menveo® and Nimenrix® are licensed for use in  individuals upto 55  years of age. The lower limit 
of age for Menactra® is 9 months, Menveo® is 2 months and Nimenrix® is 12 months.25-27 
For individuals aged 11 years and above, a single dose of either Menactra® or Menveo® should 
be administered at age 11 or 12 years, with a booster dose at age 16 years of age . Booster dose 
of Nime nrix® is not recommended. Those aged  2 to 23 months  are given  Menveo® as four -dose 
series till six months  of age or a two-dose  series  if above  that age. Whereas Menactra® should 
be used as a two dose series starting a t nine months with a minimun three  months befo re the 
second dose .25-27 
Use of TCMV has been associated with excellent safety and imm unogenicity profile, with 
reduction in incidence of me ningococcal d iseases in regions where they have been introduced 
for routine immunization.4 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 24 of 106 1.3.6.  Overall Impact of Meningococcal Vaccines  
The widespread use of conjugate meningococcal vaccines especially in higly endemic settings 
and at population level has reduced the burden of IMD drastically since pre -vaccination era. 
Inspite of this, the use of conjugate vaccine is still a big hurdle in developing world due to its high  
cost. Unlike Men A vaccine wh ich was specifically developed for the Meningitis belt in Sub -
Saharan Africa  and hence was very cost effective, the tetravalent vaccine still remains elusive for 
that kind of applic ation in this region.9, 28 
1.3.7.  Vaccine against B Serogroup  
Serogroup B meningococcus has a poorly immunogenic capsule and contains epitopes that 
potentially cross -react with human antigen, which has hindered progr ess on developing a 
polysaccharide vaccine effective against it.4, 29 
Recently, though, the FDA of USA has licensed two serogroup B meningococcal vaccine viz. 
Trumenba® and Bexsero® for use in people 10  to 25 years of age as a three -dose series and two-
dose series respectively.30-32 
1.3.8.  Vaccine against X Serogroup  
There is no vaccine available which gives protection against serogroup X which has caused many 
outbreaks in Africa and Europe in recent past.33 The WHO has expressed concerns over the lack 
of such a vaccine and has encouraged more research into it.4 
1.4. Study Vaccine  
Currently, there is no vaccine available against serogroup X of N. meningitidis . This bacterium 
has caused many outbreaks in Africa and Europe in recent past. The serogroup X has been 
responsible for outbreaks between 2006 and 2010 in Kenya, Niger, Togo, U ganda, and Burkina 
Faso, the latter with at least 1,300 cases of serogroup X meningitis among the 6,732 reported 
annual cases.33 
As a result, SII PL has developed the candidate vaccine MCV -5, which is a polyvalent conjugate 
vaccine composed of serogroups A, C, Y, W , and X of Neisseria meningitidis  capsular 
polysaccharides, conjugated to protein carriers, CRM and tetanus toxoid, with aluminum  
phosphate as an adjuvant. It is intended for the prevention of meningitis and/or septicemia caused 
by serogroups A, C, Y, W , and X N. meningitidis  in countries  where the disease is endemic and 
causes large epidemics such as the countries in the African meningitis belt. The target population 
consists of infants and children and adults aged 1 to 55 years.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 25 of 106 1.5. Summary of Nonclinical Studies  
Table 1: Preclinical Studies  
Study Title  Study Site  Study Type & 
Compliance  Animal 
Model  Sections 
in the 
protocol  
A 5-week subcutaneous dose -ranging 
immunogenicity study of monovalent 
meningococcal serotype X 
polysaccharide conjugate (MenX -TT) 
with and without aluminum phosphate 
adjuvant in mice  SIIPL  Immunogenicity  
Non-GLP Swiss albino  
mice  1.5.3.1  
A 7-week subcutaneous 
immunogenicity study of the MenX -TT 
component in the MCV -5 presentation 
with and without aluminum phosphate 
adjuvant in mice.  National  Institute for 
Biological Standards 
and Control, London 
(NIBSC), 
United  Kingdom  Immunogenicity  
Non-GLP BALB/c mice  1.5.3.2  
A 5-week intramuscular 
immunogenicity study of candidate 
SIIPL MCV -5 vaccine formulations in 
comparison to commercial vaccine in 
rabbits  SIIPL  Immunogenicity  
Non-GLP New Zealand 
white rabbit s 1.5.3.3  
A 5-week intramuscular dose -ranging 
immunogenicity study of pentavalent 
SIIPL MCV -5 vaccine (tox formulation) 
with and without aluminum phosphate 
adjuvant in rabbits  SIIPL  Immunogenicity  
Non-GLP New Zealand 
white rabbits  1.5.3.4  
A 7-week intramuscular toxicity study 
of [pentavalent] meningococcal 
(A,C,Y,W,X) polysaccharide conjugate 
vaccine (freeze -dried) in New Zealand 
white rabbits with a 6 -week recovery  MPI Research, Inc., 
54943 North Main Street 
Mattawan, MI  
49071 -8353, U.S.A.   Toxicity & 
immunogenicity 
study.  
GLP  New Zealand 
white rabbits  1.5.2.1 & 
1.5.3.5  
Series of t oxicology stud ies of 4-
Pyrrolidinopyridine (4 -PP, a byproduct 
of CPPT conjugation chemistry)  MPI Research, Inc., 
54943 North Main Street 
Mattawan, MI   
49071 -8353, U.S.A.   
and 
BioReliance,  
Rockville, MD , U.S.A.  Byproduct 
toxicology.  
Mutagenicity  
GLP  Rats,  
guinea pigs , 
prokaryotic & 
eukaryotic 
cells 1.5.2.2  
 
 
1.5.1.  Non-Good Laboratory Practice ( GLP) Nonclinical Pharmacology/Proof of 
Concept Studies  
Not Applicable  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 26 of 106 1.5.2.  Toxicology Studies  
Pre-clinical GLP toxicology study  
A repeated dose GLP toxicology study was conducted in 60 rabbits  at a GLP certified testing 
facility, MPI Research, Inc, 54943 North Main  Street, Mattawan, MI , 49071 -8353, U SA. The study 
comprised of three  groups of animals receiving  4 doses of  either  MCV -5 vaccine (5 µg of each 
serogroup antigen)  with aluminum  phosphate adjuvant, MCV -5 vaccine without adjuvant, or saline 
control  administered  2 weeks apart . All animals survived to the scheduled necropsy. There were 
no test article -related effects noted for clinical observations, ophthalmoscopic findings, body 
weights, body weight gains, food consumption, or body temperatures. No te st article -related 
alterations were observed in hematology, coagulation, or urinalysis parameters. There were no 
clear and consistent organ weight changes seen in terminal or recovery animals . Mild injection 
site reactions included very slight edema and ve ry slight erythema. These were consistent with 
injection of a vaccine and comparable to control animals injected with normal saline. Test article -
related microscopic findings were seen at the injection sites for all terminal and recovery groups. 
The inject ion site findings were not considered to be adverse, given the low severity, lack of 
systemic findings, limited serum chemistry findings, and lack of associated clinical findings.  At 
recovery, at all injection sites, there was a strong trend towards recove ry in all groups, with 
generally reduced incidence and severity of most findings compared to terminal groups. At 
recovery, at all injection sites, there was a strong trend towards recovery in all groups, with 
generally reduced incidence and severity of mos t findings compared to terminal groups.  
Toxicology study of 4 -PP (a byproduct of CPPT conjugation chemistry [in progress ]) 
A set of toxicology stud ies, of 4-PP, a residual in 1-cyano -4 pyrrolidinopyridinium tetrafluoroborate 
(CPPT) conjugation,  was also co nducted  at MPI Research, Inc  and BioReliance under 
subcontract to MP I. These included:  
a) Oral single dose in rats  
b) IM single dose in rats  
c) In vitro mutagenicity, prokaryotic cells  
d) In vitro mutagenicity, eukaryotic cells (mouse lymphoma)  
e) Skin sensitization  study  in guinea pigs  
The studies on 4 -PP suggest that this by -product is not mutagenic or clastogenic in standard 
genotoxicity assays, is well tolerated after a single intramuscular injection in rats and does not 
cause dermal sensitization in guinea pigs.   
Test article related clinical observations at oral doses of 10 and 50 mg/kg included piloerection, 
audible breathing, and vocalization whereas decreased activity, ataxia, tremors, and low carriage 
at dose of 50 mg/kg. Animals in 200  mg/kg oral dose were either euthanized in extremis or found 
dead on Day 1.  
The No -Observed -Adverse -Effect -Level (NOAEL) of 4 -PP is considered to be 10 mg/kg following 
oral administration and 0.2 mg/site following intramuscular administration. In comparison, the 
content of 4 -PP in MCV -5 vaccine is estimated to be less than 500 nanogram per dose of vaccine.  
This value is considerably  lower than the NOAEL .  
Additional details of these toxicology studies are available in the investigator’s brochure (IB).  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 27 of 106 1.5.3.  Immunogenicity  Stud ies  
Immunogenicity study of monovalent MenX tetanus toxoid conjugate vaccine (MenX -TT) 
in mice  
This study was conducted in Swiss albino mice at SIIPL, India. The study results presented in 
Table 2 show that immunization with MenX -TT PS conjugate elicits antibo dy responses to 
MenX  PS, as measured by both IgG immunoassay and rSBA. IgG responses were low and rSBA 
antibody responses were undetectable  for the group of mice immunized with adjuvanted native 
MenX  PS (Group 1, Table 2) . Immunization with either 0.5 µg or 1.0 µg of MenX -TT conjugate 
was highly immunogenic and generated strong bactericidal activity  after three  doses ( Days 0, 14, 
28), suggestive of a T -cell dependent immune response. The addition of aluminum phosphate 
adjuvant further improved IgG and rSBA titers, particularly at the 0.5 dose level  (Groups 3 and 4, 
Table 2) . These data suggest that that the MenX-TT conjugate is immunogenic and could be 
included in a polyvalent meningococcal conjugate vaccine.  
Table 2: Day 35 Serum IgG Titers to MenX after Three Immunizations with MenX -TT 
Group  Treatment  Amount per 
dose (µg)  IgG titer  
(GMT)  rSBA titer  
(GMT)  
1 Saline  - 50 <4 
2 Native MenX PS + aluminum phosphate  0.5 + 125  1,600  4 
3 MenX -TT conjugate  0.5 6,400  42 
4 MenX -TT conjugate + aluminum phosphate  0.5 + 125  40,637  128 
5 MenX -TT conjugate  1.0 51,200  341 
6 MenX -TT conjugate + aluminum phosphate  1.0 + 125  51,200  512 
 
Immunogenicity of the MenX -TT Component of MCV -5 Vaccine in BALB/c Mice  
This study was conducted in BALB/c mice at National Institute for Biological Standards and 
Control (NIBSC), UK, to confirm and further evaluate the immunogenicity of the MenX -TT PS 
conjugate antigen, with and without aluminum phosphate adjuvant, when combined with the other 
four meningococcal PS  conjugates (MenA -TT, MenC -CRM, MenY -CRM and MenW -CRM) 
intended to be included in the pentavalent SIIPL MCV -5. Groups of 20 young adult female BALB/c 
mice were immunized subcutaneously with either MCV -5 with aluminum phosphate or MCV -5 
without adjuvant or licensed quadrivalent Menveo® PS conjugate vaccine as a control.  
Vaccination was on days 0, 14, 28 with each mouse receiving  1/10th of a human dose  of the test 
vaccines at each time point  
As expected, the antibody titers  to MenX  for the animals that were immunized with Menveo®, 
which does not contain a MenX PS conjugate component, were low at all bleed time points ( Study 
Days 1 4, 28, and 42) and reached a maximum relative log GMT of 1.4 5 units/mL at study day 42 
(2 weeks post -3rd dose) as presented in Table 3.  An increase in MenX -specific antibody titers 
was observed in animals immunized with MCV -5 and without aluminum phosphate  following the 
second dose, and additional increases were observed after the third dose. Additionally, the MenX -
specific antibody responses to MCV -5 with aluminum phosphate adjuvant were higher than those 
to MCV -5 without adjuvant, and this difference was most pronounced at study day 42 (post 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 28 of 106 dose  3). Taken as a whole, these results clearly demonstrate that the MenX -TT antigen is robustly 
immunogenic when combined with the other four polysaccharide conjugate antigens (MenACYW) 
in MCV -5 and that addition of aluminum phosphate adjuvant improves its immunogenicity.   
Table 3:  Geometric Mean Serum IgG Titers to MenX  
Group  Vaccine Treatment  Day 14  Day 28  Day 42  
GMT 
(95% CI)  GMT 
(95% CI)  GMT 
(95% CI)  
1 MCV -5 
(Adjuvanted)  0.29 
(0.11 – 0.82)  43.89  
(19.31 -99.75)  140.23  
(96.49 -203.81)  
2 MCV -5 
(Unadjuvanted)  0.33 
(0.17 -0.65)  34.05  
(17.19 -67.45)  63.39  
(47.60 -84.42)  
3 Menveo® 0.02 
(0.02 -0.04)  0.74 
(0.29 -1.89)  1.45 
(1.11 -1.89)  
 
Immunogenicity  of Candidate SIIPL MCV -5 Formulations in New Zealand White Rabbits  
The immunogenicity of three different candidate formulations of adjuvanted SIIPL MCV -5 were 
evaluated in New Zealand white rabbits in a study conducted at SIIPL . The adjuvanted F3 
formulation selected for clinical development had the best immunogenicity profile compared to 
the other two adjuvanted formulations (F2 and F4).  Additionally,  the adjuvanted F3 formulation 
elicited comparable or better immune responses to serotypes MenA, C, Y and W than did  
Menveo® (Table s 4 and 5 ). Additional details of this study are available in the IB. 
Table 4: Geometric mean IgG titers to MenA,C,Y,W and X  
Vaccine Treatment  Study 
Day rSBA antibody responses  
(GMTs)  
MenA  MenC  MenY  MenW  MenX  
Menveo® 0 50 50 50 50 n.d. a 
35 44,572  25,600  38,802  29,047  n.d. a 
SIIPL MCV -5 F2 with 
aluminum phosphate 
adjuvant  0 50 50 50 50 50 
35 72,408  51,200  72,408  60,887  60,887  
SIIPL MCV -5 F3 with 
aluminum phosphate 
adjuvant  0 50 100 50 50 200 
35 58,813  58,813  117,627  89,144  51,200  
SIIPL MCV -5 F4 with 
aluminum phosphate 
adjuvant  0 50 100 50 50 50 
35 33,779  9,701  29,407  25,600  51,200  
a No data (n.d.) because Menveo® does not contain a MenX component .  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 29 of 106 Table 5: Geometric mean bactericidal antibody titers to MenA,C,Y,W and X  
Vaccine Treatment  Study 
Day rSBA antibody responses  
(GMTs)  
MenA  MenC  MenY  MenW  MenX  
 Menveo® 0 2 2 4 2 n.d.a 
35 446 223 256 223 n.d.a 
SIIPL MCV -5 F2 with aluminum 
phosphate adjuvant  0 2 2 2 2 16 
35 724 215 152 256 1,024  
SIIPL MCV -5 F3 with aluminum 
phosphate adjuvant  0 2 2 2 2 8 
35 676 512 388 588 1,024  
SIIPL MCV -5 F4 with aluminum 
phosphate adjuvant  0 2 2 2 2 2 
35 338 64 111 147 676 
a No data  (n.d.) because Menveo® does not contain a MenX component.  
 
Immunogenicity of the SIIPL MCV -5 vaccine in New Zealand White Rabbits  
The immunogenicity of the first cGMP lot of the pentavalent SIIPL MCV -5 vaccine was also 
evaluated in New Zealand white rabbits at SIIPL. Groups of adult New Zealand white rabbits were 
dosed with either MCV -5 reconstituted with diluent with and wit hout 125 µg aluminum phosphate 
adjuvant , the licensed quadrivalent vaccine Menactra® or the licensed quadrivalent vaccine  
Menveo®. The dose of MCV -5 was 5 µg per PS conjugate component in the vaccine. The dose 
of Menactra® was 4 µg per PS conjugate component in the vaccine. The dose of Menveo® was 
10 µg of MenA PS conjugate and 5 µg each for the MenC, Y and W PS conjugate components in 
the vaccine.  Animals were immunized by intramuscular injection on Days 0, 14 and 28.  
In summary, the IgG and bactericidal (rSBA) antibody response results from this study clearly 
demonstrate that MCV -5 was strongly immunogenic for all 5 meningococcal serotypes (A, C, Y, 
W and X) represented in the vaccine and that addition of aluminum phosphat e adjuvant improved 
its immunogenicity. Additionally, adjuvanted MCV -5 had comparable or better immunogenicity for 
the meningococcal serotypes A, C, Y, and W than the licensed vaccines Menveo® and Menactra®. 
Additional details of this study are available i n the IB.  
MPI rabbit immunogenicity study of all five serogroups  
This GLP study evaluated the immunogenicity of adjuvanted and non -adjuvanted MCV -5 vaccine 
in adult New Zealand White rabbits following four bi -weekly intramuscular doses given for seven 
week s in rabbits and after a six-week recovery period. Immunogenicity was measured by rSBA 
with regards to titers  of IgG antibodies against all five serogroups in serum samples collected on 
Days 1 and 43.  A third group of rabbits received saline as control . The sample size in each of the 
groups was 20 (10 males and 10 females).  
For all three  groups , no IgG response s were seen from the Day 1 pre -immune sera agai nst any 
of the m eningococcal serogroups. The Day 43 saline control Group 1 had similar geometric mean 
IgG concentrations to those obtained in the Day 1 pre immune sera across all serogroups. The 
Day 43 group immunized  with MCV -5 vaccine with or without adjuvant gave a res ponse against 
all serogroups that was significantly greater than the saline control group.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 30 of 106 Higher antibody concentrations were observed in sera when aluminum  phosphate was used as 
an adjuvant, with increases ranging from 49% to 165%. Serogroups A, Y, and X all showed a 
statistically significant increase in antibody concentration compared to the group without adjuvant. 
However, for serogroups C and W, this observed difference between the two groups did not reach 
statistical significance. Additional details of this study are available in the IB . 
In summary, this study showed that the MCV -5 pentavalent vaccine formulation produced a strong 
immune response against all five serogroups. The addition of adjuvant resulted in an increase in 
immune response for all f ive serogroups with a statistically significant increase for three 
serogroups.   
1.6. Clinical Studies  
No human data is available as of now and  the pre sent first-in-human study on MCV -5 vaccine  is 
being conducted with primary objective of assessing the vaccine’s  safety in an adult population.  
There is no clinical data available on potential safety risks, although it is anticipated that the 
vaccine will have a safety profile similar to that of currently licensed vaccines against 
meningococci including Menactra® (reference vaccine in present study) and MenAfriVac®. 
Apart from local solicited reactions such as pain, erythema, induration and swelling , other 
common (≥10%) solicited systemic reactions in adults (18  to 55 years) who received Menactra® 
included  headach e, malaise, fatigue, arthralgia, diarrhea  and anorexia.26 Solicited reaction s were 
considered those occurring within seven  days of vaccination.  
Clinical trial of MenAfriVac® conducted in 18  to 29 year old s showed post vaccination local and 
systemic reactions to be comparable  to Menveo® with headach e as the most commonly reported 
reactions (12%) followed by tenderness (6%).  Other reactions such as fever, vomiting, fatigue, 
myalgia and arthralgia were infrequent (2.5% to less than 1%) .34 
2. HYPOTHESIS, SCIENTIF IC RATIONALE, OBJECT IVES AND STUDY DESIG N 
2.1. Study Hypothes es 
The proposed Phase 1 study will test the following hypothes es: 
a. Primary hypothesis:  Two formulations (adjuvanted and non -adjuvanted) of  MCV -5 vaccine 
when given to healthy adults will be safe and well tolerated . 
b. Secondary hypothesis: Two formulations (adjuvanted and non -adjuvanted) of MCV -5 
vaccine when given to healthy adults will induce  immune response to all the five 
serogroups of the vaccines.  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 31 of 106 2.2. Scientific Rationale  
Currently, three conjugate polyvalent vaccines are available to protect against meningococcal 
disease. All three are tetravalent (serogroups A, C, W and Y) vaccines; Menact ra® (Sanofi Pasteur 
Inc.), Menveo® (Novartis) and Nimenrix® (Glaxo SmithKline Beecham). There is large experience 
with the use of these vaccines, which are generally well tolerated in all age groups. At this time, 
there is no licenced vaccine giving protec tion against serogroup X which has caused many 
outbreaks in Africa and Europe in recent past.  
Following the MenAfriVac® MenA monovalent conjugate vaccine development experience, SIIPL  
has developed a candidate polyvalent conjugate vaccine composed of serogroups A, C, Y, W and 
X Neisseria meningitidis  capsular polysaccharides. This candidate MCV -5 is conjugated to protein 
carriers, CRM and tetanus toxoid, and formulated with or without aluminum  phosphate as an 
adjuvant. It is intended for the prevention of meningitis and/or septicemia caused by serogroups 
A, C, Y, W , and X N. meningitidis in countries where the disease is endemic and causes large 
epidemics such as the countries in the Af rican meningitis belt. The target population consists of 
infants, children and adults aged 1 to 55 years.  
This first Phase 1 clinical study is designed to evaluate primarily the safety of the study vaccine. 
The three -group design of the study will allow sa fety evaluation of the adjuvanted and non-
adjuvanted  MCV -5 formulations. The Menactra® vaccine has been chosen as control vaccine for 
the large safety database accumulated since the vaccine has been introduced in the USA in 2005 
and progressively in other countries.9, 35 
In addition, secondary immunogenicty evaluation is planned on both adjuvanted and 
non-adjuvanted  formulations.  
This Phase 1 study will be performed in adult healthy volunteers aged 18  to 45 years of age.  
2.3. Overall Clinical Development Strategy  
SIIPL  has developed MCV -5 with an aim to license and make it available particularly in developing 
markets including Africa. Once the results of current study are available, b oth the adjuvanted and 
non-adjuvanted formulations will further be compared for i mmune response in a Phase 2 clinical 
trial among toddlers. Results  of this Phase 2 study will help decide which one of the formulations 
to be carried into the next phases of clinical development.   
2.4. Study Design  
This is a Phase 1, single center, double -blind, randomized, controlled clinical trial to be performed 
in 18  to 45 year old healthy volunteers.  
The study will have three arms with three vaccines given in a 1:1:1 ratio: adjuvanted MCV -5, non -
adjuvanted MCV -5 and Menactra® given as a single intram uscular injection. All participant s will 
be followed up for six months after the vaccination.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 32 of 106 2.4.1.  Discussion of Study Design  
The three -group design of the study will allow comparison of the adjuvanted and non-adjuvanted  
ACYWX safety profile with that of a li censed ACYW conjugate vaccine (reference vaccine group).  
The vaccinator will be aware of group allocation, although he/she will not be able to influence or 
decide this allocation  nor be part of the safety assessment . This will ensure that the study team , 
involved in assessment  of safety outcome as well as participant s, are unaware of the identity of 
study vaccine administered to them. This will help rule out the bias at the time of assessment.  
As the reference product and study vaccines are different in appearance and composition, the 
vaccinator blind cannot be maintained in this study. However  the vaccinator is not involved in  
safety assessment.  
In addition, immunogenic ity assessments are plann ed to evaluate any difference in the immune 
responses induced by the adjuvanted and non-adjuvanted  study vaccines and to compare against 
the reference vaccine. The study , however,  is not statistically powered to determine significance 
of any  difference.  There is neither any formal sample size calculation as this is a Phase 1 trial. 
As this is the first clinical study with the study vaccine, the study will be initially performed in adult 
healthy volunteers . 
2.4.2.  Primary Objective  
To evaluate the safety of adjuvan ted and non -adjuvanted formulations of MCV -5 vaccine . 
2.4.3.  Secondary Objective  
To assess the immune response of adjuvanted and non -adjuvanted formulations of MCV -5 
vaccine . 
2.4.4.  Primary Endpoints  
 The occurrence and severity of solicited local and systemic post immunization reactions 
within seven  days following vaccination .  
 The occurrence, severity, and  relatedness of unsolicited adverse events for 28 days 
following vaccination, and serious adverse events for 6 months following vaccination . 
2.4.5.  Secondary Endpoints  
 The percentage of participant s who show a seroconversion for Meningococcal 
Polysaccharide A, C, Y, W and X specific antibodies, i.e. a ≥4 -fold increase in post -
immunization rSBA titer with respect to pre -immunization rSBA titer, at 28 d ays after a 
single vaccine dose . 
 The percentage of participant s who show a post -immunization seroprotection titer for 
Meningococcal Polysaccharide A, C, Y, W , and X specific antibodies defined as rSBA titer 
of 1:8 and 1:128 at 28 days after a single vaccin e dose . 
 GMTs of Meningococcal Polysaccharide A, C, Y, W and X specific antibodies at 28 days 
after a single vac cine dose, as measured by rSBA assay . 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 33 of 106 2.4.6.  Exploratory Endpoints  
Additional i mmune response of  adjuvanted  and non -adjuvanted formulations of MCV -5 may be 
assessed  by other relevant assays  if remaining specimen  volume is adequate .  
2.4.7.  Randomization and Vaccination  
This is a prospective, randomized, parallel group, double blind clinical study. For arm allocation, 
a randomization -blocking scheme (1:1:1) w ill be used. Each block will be of six participant s. The 
vaccine will be supplied to the study site while respecting the randomization block size.   
The vaccine will be administered sequentially depending upon the randomization number by 
unblinded clinical staff not involved with the clinical assessment of study participants . Other 
investigative site personnel will not be aware of which group the participant has been randomized. 
The identity of the same cannot be revealed except in an emergency.  Study monito r will verify 
randomization by checking the treatment allocation against the vaccination records at each study 
visit. 
 
3. STUDY PRODUCT S 
3.1. Test Vaccine (MCV -5) 
3.1.1.  Product Description  
Serum Institute of India  Private Limited ’s candidated vaccine MCV -5 is a sterile  pentavalent 
polysaccharide -conjugate vaccine composed of serogroups A, C, Y, W and X  Neisseria 
meningitidis  capsular polysaccharides, conjugated to two different protein carriers, with aluminum  
phosphate as an adjuvant. Serogroup A & X polysaccharide are separately conjugated to tetanus 
toxoid  while C,  Y & W are separately conjugated to recombinant CRM (CRM is genetic mutant of 
diphtheria toxin) . 
It is intended for  intramuscular administration and protects against meningitis and/or septicemia 
caused by ser ogroups A, C, Y, W , and X N meningitidis.  
N. meningitidis  A, C, Y, W , and X polysaccharides are produced by cultivating cells in fed batch 
fermentation and purified after separation . Tetanus toxin is derived from Clostridium tetani  grown 
in a modified medi um and purified. CRM  is expressed by Pseudomonas fluorescens  strain and 
used after it is purified.  Meningococcal polysaccharides are covalently  conjugated to TT  or CRM  
and purified to make the final formulated vaccine.  Screening  
Randomization  Group 1 (n=20): Study Group  
Adjuvanted MCV -5 conjugate vaccine  
Group 2 (n=20): Study Group  
Non-adjuvanted  MCV -5 conjugate vaccine  
Group 3 (n=20): Study Group  
Menactra® 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 34 of 106 3.1.2.  Manufacturer  
Serum Institute of India Private Limited , Pune  
3.1.3.  Presentation and Formulation  
The MCV -5 vaccine is provided as a freeze -dried powder in a five-dose vial containing 
meningococcal A, C, Y, W , and X polysaccharides conjugated to tetanus toxoid and CRM protein. 
The vaccine has to be reconstituted with either adjuvant containing diluent s or 0.9% Sodium 
Chloride Injection, USP  as per sections 3. 2 and 3.4. (Further details regarding preparation of 
adjuvanted and non -adjuvanted MCV -5 are provided in the protocol specific Pharmacy Manual.) 
No preservative is added either in vaccine or diluents component during manufacture.   
Vaccine Composition of 5 dose vial of MCV -5 vaccine  (freeze dried)  
Component  Quantity  
Meningococcal A polysaccha ride* 30 g 
Meningococcal C polysaccharide# 30 g 
Meningococcal Y polysaccharide# 30 g 
Meningococcal W polysaccharide# 30 g 
Meningococcal X  polysaccharide*  30 g 
Sucrose  15 mg  
Sodium Citrate  2.5 mg  
Tris (Trometomol)  0.61 mg  
* - Conjugated to Tetanus Toxoid (TT); #  - Conjugated to CRM ; q.s. - Quantum satis  
 
3.1.4.  Stability and Storage  
MCV -5 vaccine must be stored  between +2°C to +8 °C. 
3.2. Diluent s 
3.2.1.  Adjuvanted Diluent  
Product Description  
The adjuvanted diluent containing aluminum  phosphate used to prepare the adjuvanted MCV -5 
is a sterile white homogeneous suspension presented in a glass ampoule.  
Manufacturer  
Serum Institute of India Private Limited , Pune  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 35 of 106 Presentation and Formulation  
The adjuvant containing diluent is provided in a five-dose glass ampoule containing an actual fill 
volume of 3.1 mL  ± 0.1 mL. Each 0.5 mL  of adjuvanted diluent contains 125 µg Al3+ formulated 
in 0.9% Sodium Chloride.  
Stability and Storage  
The adjuvanted diluent must be stored between +2°C to +8°C  and not to be frozen.  
3.2.2.  Non-Adjuvanted Diluent  
0.9% Sodium Chloride Injection, USP, will be used to prepare t he non-adjuvanted MenACYW X 
vaccine.  The research pharmacy at the site will procure  enough supply of the same lot of  0.9% 
Sodium Chloride Injection t o complete the study.  The 0.9% Sodium Chloride  Injection will be 
stored at 20°C - 25°C.   
3.3. Reference Vaccine ( Menactra®)26 
3.3.1.  Product Description  
Menactra® is a sterile, intramuscularly administered q uadrivalent conjugate vaccine composed of 
serogroups A, C, Y, and W  Neisseria meningitidis  capsular polysaccharides, conjugated to a 
protein carrier, diphtheria toxoid protein , without any adjuvant. It is intended for the prevention of 
meningitis and/or septicemia caused by serogroups A, C, Y, and W N. meningitidis . 
N. meningitidis  A, C, Y , and W-135 strains are cultured on Mueller Hinton agar and grown in 
Watson Scherp media containing casamino acid.  
3.3.2.  Manufacturer  
Sanofi Pasteur Inc. 
3.3.3.  Presentation and Formulation  
Menactra® vaccine is a clear to slightly turbid solution  supplied in 0.5 m L single dose vial . Each 
0.5 mL dose of vaccine  is formulated in sodium phosphate buffered isotonic sodium chloride 
solution to contain four mcg each of meningococcal A, C, Y , and W -135 polysaccharides 
conjugated to approximately 48 µg of diphtheria toxoid protein carrier and residual amounts of 
formaldehyde of less than 2.66 µg (0.000532%), by calculation.   
3.3.4.  Stability and Storage  
Menactra® must be stored between  +2°C to +8 °C. 
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 36 of 106 3.4. Preparation and Administration  
Participants will be randomized 1:1:1 to receive e ither adjuvanted MCV -5 or non -adjuva nted 
MCV -5 or Menactra®. The vaccination will be administered by a staff not involved with the clinical 
assessment of study participants.  
3.4.1.  Adjuvanted MCV -5 
The adjuvanted MCV -5 is prepared by reconstituting one vial of MCV -5 with a single ampoule of 
adjuvant containing diluent.  For each participant, 0.5 mL dose will be withdrawn from the 
reconstituted five -dose adjuvanted MCV -5 vaccine vial using a sterile needle and syringe. For the 
purpose of this study one vial of rec onstituted adjuvanted MCV -5 will be used for only one 
participant.  After reconstitution the vaccine must be used as soon as possible but not later than 
two hours, during which time it may be kept at room temperature but must not be frozen.  The 
single dose of 0.5 mL vaccine as per randomization schedule will be given via intramuscular 
injection using a needle and syringe in the deltoid muscle.   
The compositions of a single 0.5 mL dose of reconstituted adjuvanted MCV -5 vaccine are:  
Vaccine component  Per 0.5 m L dose  
Meningococcal A polysaccharide*  5 g 
Meningococcal C polysaccharide# 5 g 
Meningococcal Y polysaccharide# 5 g 
Meningococcal W polysaccharide# 5 g 
Meningococcal X  polysaccharide*  5 g 
Sucrose  2.42 mg  
Sodium Citrate  0.40 mg  
Tris (Trometomol)  0.098 mg  
Al3+adjuvant  125 g  
0.9% Sodium Chloride  q. s.  
 
 
 
 Tetanus Toxoid  7.8 to 33.4 µg  
CRM  11.7 to 50.1 µg  
*- Each conjugated to  Tetanus Toxoid (TT);  
# - Each c onjugated to CRM ; 
q.s. - Quantum satis  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 37 of 106 3.4.2.  Non-Adjuvanted MCV -5 
The non -adjuvanted MCV -5 is prepared by reconstituting one vial of MCV -5 with a 3.1 mL of 0.9% 
Sodium Chloride Injection, USP.  For each participant, 0.5 mL dose will be withdrawn from the 
reconstituted five -dose non -adjuvanted MCV -5 vaccine vial using a sterile needle and sy ringe. 
For the purpose of this study one vial of reconstituted non -adjuvanted MCV -5 will be used for only 
one participant.  After reconstitution the vaccine must be used as soon as possible but not later 
than two hours, during which time it may be kept at r oom temperature but must not be frozen.  
The single dose of 0.5 mL vaccine as per randomization schedule will be given via intramuscular 
injection using a needle and syringe in the deltoid muscle.   
The compositions of a single 0.5 mL dose of reconstituted  non-adjuvanted  MCV -5 vaccine are:  
Vaccine component  Per 0.5 mL dose  
Meningococcal A polysaccharide*  5 g 
Meningococcal C polysaccharide# 5 g 
Meningococcal Y polysaccharide# 5 g 
Meningococcal W polysaccharide# 5 g 
Meningococcal X  polysaccharide*  5 g 
Sucrose  2.42 mg  
Sodium Citrate  0.40 mg  
Tris (Trometomol)  0.098 mg  
Tetanus Toxoid  7.8 to 33.4 µg  
CRM  11.7 to 50.1 µg  
* - Each conjugated to Tetanus Toxoid (TT);  
# - Each conjugated to CRM ;  
q.s. - Quantum satis  
 
3.4.3.  Menactra® 
After inspecting and confirming visually for particulate matter and discoloration 0.5 mL dose of 
vaccine is to be withdrawn from the single -dose vial using a sterile needle and syringe. The single 
dose of 0.5 mL vaccine as per randomization schedule will b e given via intramuscular injection 
using a needle and syringe in the deltoid muscle. Vaccine must be administered within two hours 
of preparation.  
3.5. Accountability and Disposal  
Test vaccine  MCV -5 and diluent used for reconstitution of adjuvanted formulation  (sodium 
chloride plus aluminum phosphate) will be provided by SIIPL  and shipped to the study site in 
validated cold chain boxes. The investigator will acknowledge receipt of products indicating 
shipment content and condition.  
Whereas, site may arrange to directly procure Menactra® as well diluent for non -adjuvanted 
formulation (sodium chloride) . In case it is not feasible for site, the same will be arranged by 
sponsor/designee . 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 38 of 106 The SIIPL  supplied vaccine will be packed in appropriate package deemed to maintain the 
integrity of the product. The packaging for Menactra® will be the same as that available in market 
at the time of procurement.  
Additional labels will be affixed on all study vac cines and diluents which should specify a statutory 
statement : ‘Caution: New Drug --Limited by Federal law to investigational use ’.  
The label should also have following details:  
 Name of Manufacturer  
 Protocol number  
 Store between 2 ° and 8°C 
A participant identifier will be captured or pre -printed on vaccine labels to ensure accountability 
and traceability to the study subject for which they were used.  
All vaccines used in the study must be accounted for in the Vaccine Accountability Record .  
Investigator or an authorized representative of the investigator will ensure that all vaccines will be 
stored in a secured area, in a light protected, dry place at temperature between +2°C and +8°C. 
Storage temperature should be monitored every day.  
Qualifie d staff members will administer the vaccine.  
The investigator must maintain a temperature log and an inventory record of vaccines received 
and administered.  
At the end of the study, all vaccine will be destructed at the site , as per site’s standard operat ing 
procedure  or returned to SIIPL , including vaccine not administered to participant s. It will be 
ensured that destruction occurs only after study product accountability.  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 39 of 106 4. STUDY POPULATION  
4.1. Clinical Trial Site  
This will be a single site study conducted at  the Center for Vaccine Development (CVD), University 
of Maryland, Baltimore USA.  
4.2. Study Population  
Healthy adult volunteers, 18 to 4 5 years of age.  
4.3. Eligibility  
4.3.1.  Inclusion Criteria  
Male and female participant s will be eligible for inclusion if ALL of the following apply at the time 
of screening:  
1. Age 18 to 45 years of age  inclusive   
2. Written informed consent of volunteers  
3. Healthy  as established by medical history, laboratory evaluation and screening evaluations 
including clinical physical examination  
4. Partici pants must have the following laboratory parameters:  
a. Hemoglobin:  ≥ 10.5 g/dL for female, ≥ 1 1.0 g/dL for male  
b. White cell count: 3,300 to 12,000 cells/ mm3  
c. Platelets: 125,000 to 550,000/ mm3  
d. ALT < 1.25 times the institutional upper limit of normal (ULN)  
e. Creatinine and total bilirubin ≤ institutional ULN  
f. Albumin ≥ institutional lower limit of normal  
5. Participants are able to understand and comply with planned study procedures and be 
available for  all study visits   
6. Female subjects must be of non -childbearing  potential (defined as surgically sterile or 
postmenopausal for more than 1 year), or if of childbearing potential must be practicing 
abstinence or using an effective licensed method of birth control (e.g., history of 
hysterectomy or tubal ligation; use ho rmonal or barrier birth control such as implants,  
injectables, combined oral contraceptives, some intrauterine devices (IUDs), cervical 
sponges, diaphragms, condoms with spermicidal agents; or must have a vasectomized 
partner) within one month of vaccinati on and must agree to continue such precautions for 
84 days after vaccination. A woman is eligible if she is monogamous with a vasectomized 
male . 
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 40 of 106 4.3.2.  Exclusion Criteria  
Participants  with any of the following criteria at study entry will not be eligible for participation:  
1. Previous vaccination against Neisseria meningitid is. 
2. Known exposure to Neisseria meningitidis  in the past . 
3. History of meningitis or seizures or any neurological or psychiatric disorder . 
4. Administration of any other vaccine within 30 days prior or after administration of study 
vaccines . 
5. Use of any investigational or non -registered drug or vaccine within 30 days prior to the 
administration of study vaccines or planned d uring the study.  
6. History of allergic disease or known hypersensitivity to any component of the three study 
vaccines . 
7. History of Serious Adverse Reactions following administration of Tetanus Toxoid , Diphtheria 
Toxoid or CRM  containing  vaccine s. 
8. History of Guillain -Barré  syndrome . 
9. Confirmed or suspected immunosuppressive or immune -deficient condition . 
10. A family history of congenital or hereditary immunodeficiency . 
11. Chronic administration (defined as more than 14 days) of immune -suppressants or other 
immune -modifying agents within six months prior to administration of study vaccine. (For 
corticosteroids, this means prednisone, or equivalent, > 0.5 mg/kg/day; topical o r inhalable 
steroids are allowed.)  
12. Laboratory confirmed infection of either hepatitis B virus (HBs Ag positive on ELISA), 
hepatitis C virus (anti -HCV positive on ELISA as well as PCR) or human immunodeficiency 
virus (HIV on ELISA) . 
13. Major congenital defects  or serious chronic illness . 
14. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional 
abnormality, as determined by medical history, physical examination or laboratory screening 
tests.  
15. Known bleeding disorders . 
16. Admi nistration of immunoglobulins and/or any blood products within the three months 
preceding the administration of study vaccines or planned administration during the vaccine 
period . 
17. History (within the past year) or signs of alcohol or substance abuse.   
18. Preg nancy or lactation. A negative pregnancy test will be required before vaccination for all 
women of childbearing potential.  
19. A Body Mass Index (BMI) above 30. 
20. Any other condition, which in the opinion of the investigator, might interfere with the study 
objec tives, jeopardize the safety or rights of the participant  or making it unlikely the participant  
could complete the protocol.  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 41 of 106 5. STUDY PROCEDURES  
The study will be started only after the written approval from appropriate regulatory authority and 
the respecti ve site ’s ethics committees are obtained.  
The study Principal Investigator (PI) will ensure that the study team adheres to good clinical 
practices (GCP). Study personnel will be required to:  
 Maintain control and retention of primary source documents and electronic databases with 
passwords, back -up, and restrict the ability to change results.  
 Avoid coercive means of recruitment.  
 Avoid excessive compensation that leads to the inclusion of participants who would 
otherwise be ineligible.  
 Report adverse events  and routine data to the external monitoring committee per the 
monitoring plan.  
 Comply with the local regulatory and GCP requirements for vaccine -related adverse event 
reporting.  
 Use infection control/biosafety measures to reduce exposure to infectious dis eases, 
including during the transport of specimens.  
 Report any anticipated changes to the protocol (such as randomization plan revisions) to 
the ethics committees and have approval s from such committees prior to initiating 
changes . 
5.1. Recruitment  
Participants  may be recruited from the CVD volunteer database and by local advertisements and 
flyers. Potential participants  who are interested in the study will be informed of the study and if 
they wish to participate, will receive additional study information, inclu ding the informed consent 
form.  
5.2. Screening, Randomization, Masking Procedures , Stud y Visits  
5.2.1.  Initial and Continuing Informed Consent  
Informed consent is the process of ensuring that study participant s fully understand the purpose 
of the study and what will a nd may happen to them while participating in a research study. Initial 
written informed consent is required before performance of any study -related procedures. The 
informed consent process continues throughout the study. Key study concepts are reviewed wit h 
the participant at  designated times and as needed, and the review is documented.  
Additionally, if any new information becomes available that, in the judgment of the Sponsor and/or 
PI, may affect the participant ’s decision to continue in the trial, such information will be shared 
with the study participant  and may be the basis for requiring a new consent form  to be signed.  
A copy of the signed informed consent form (ICF) will be provided to the participant  and the 
original ICF will be filed with the participant ’s study record.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 42 of 106 5.2.2.  Screening , Visit 1 (Day -28 to -1) 
Once informed consent has been obtained the participant  will be considered enrolled in the trial.  
The following procedures will be completed during screening to determine study eligibility and 
may occur over multiple screening visits . Additional screening visits may be scheduled for any 
follow up as needed, but are not required. At the screening visit(s), the PI or designee will provide 
prospective volunteers with a detailed description of the study  objectives and study participation 
requirements, as well as potential health risks and benefits associated with study participation.  
Baseline data are obtained during screening, which may occur over the course of several 
contacts/visits, between 28 days p rior to and on Day 1, the day of vaccination . All 
inclusion/exclusion criteria must be assessed from data obtained within that period, unless 
otherwise specified in the eligibility criteria. After study information has been provided and the 
appropriate inf ormed consent has been obtained, the following procedures are performed  by 
PI/designee : 
a) Confirms that written informed consent has been given and solicits and discusses any 
remaining questions the participant may have;  
b) Assign screening number  once study specific consent form has been signed;  
c) Obtain demographic and contact (e.g., address, telephone, email) information;  
d) Obtain medical history;  including history of any vaccination in the last 30 days and ever 
received  vaccination  against Neisseria meningitid is, tetanus or diphtheria containing 
vaccines  
e) Obtain history of medication use in the past 30 days;  
f) Measure height & weight;  
g) Perform full physical exam , including vital signs  (blood pressure, pulse and temperature – 
section 5.5.1 ); and  
h) Collect blood samples (18 mL) for screening laboratory testing: hematology (hemoglobin, 
platelet count and WBC), clinical chemistry (creatinine, albumin, ALT  and total bilirubin ), 
serum HCG pregnancy test (females of childbearing potential only) and screen ing for HIV, 
HCV and HBV (Appendix I).  
5.2.3.  Randomization  
Enrollment will be performed online using the enrollment module of AdvantageEDCSM, the E mmes  
Corporation’s electronic data capture (EDC) system.  Randomization will occur on the day 
participants are to receive their first study vaccination , after confirmation of eligibility and 
immediately prior to vaccination .  
Participant s will be assigned to a coded treatment assignment after demographic and elig ibility 
data have been entered into the system. The unblinded pharmacist will be provided with the 
treatment assignment codes for preparation of the vaccine to be given to each participant . The 
research pharmacist will maintain the treatment code list in a  secure place.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 43 of 106 Based on this randomization schedule  each participant  will be assigned to one of the following 
three treatment groups:  
Grou p Vaccine  
1 Adjuvanted Study vaccine ( MCV -5) 
2 Non-adjuvanted Study vaccine ( MCV -5) 
3 Reference vaccine ( Menactra®, ACYW)  
5.2.4.  Vaccination , Visit 2 (Day 1) 
Prior to Vaccine Administration  
a) Obtain  interim  medical  and medications  history to confirm continued eligibility ; 
b) Measure v ital signs;  
c) Perform targeted physical exam  based on  complaints,  interval history and to confirm 
absence of abnormality at the injection site (deltoid) ;  
d) For female participants  of child bearing potentia l, perform urine  or serum  pregnancy test ;  
e) Obtain b lood samples  (20 mL)  for immunological testing; and 
f) Record  randomization  code for eligible participant  
Vaccine Administration  
a) The prospective injection site will be cleaned with an alcohol swab and allowed to dry 
completely. The study injection will be administered into the deltoid by inserting the needle 
(25 gaug e, 25 mm) into muscle at 90°, holding the muscle mass stable with the non -
injecting hand, and slowly depressing the plunger. The needle is removed and the injection 
site gently rubbed with  gauze . 
b) An unblinded clinical staff not invol ved with clinical assessment  will administer the 
assigned vaccine to the participant . 
c) Document on the CRF as to timing and location of vaccine administration.  
Post Dose – Observation Period  
a) Participants will remain at the site for at least 60 minutes post-vaccination . 
b) After  60 minutes  study staff will assess and record oral temperature, systemic  (headache, 
fatigue /malaise , myalgia, arthralgia , diarrhea and anorexia ) and local injection site (pain, 
redness/erythema, swelling/induration) reactions . 
c) The PI (or designee) may det ermine that a participant  requires further on -site 
observation; or clinical assessments as needed.  
d) When all study related procedures are complete and the PI (or designee) determines that 
a participant ’s condition is acceptable, the participant  will be discharged from study site.  
e) Before discharge, the participant  will be provided with supplies including a thermometer, 
injection site measuring device , and a Memory Aid ; instructed in their use ; and provided 
with written materials, follow -up visit informati on, and contact telephone numbers for study 
staff.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 44 of 106 5.2.5.  Visit 3 (Day 8 +3 days) 
On the eighth  day after vaccination , the participant  will return to the study site for the following 
procedures:  
a) Study staff review and record  participant’s  interim health history,  medication use  and self -
assessment experience through personal interview, assisted by the Memory Aid .  
b) Vital signs, injection site, and a targeted physical examination  (if indicated)  will be 
performed.  
c) Local and systemic reactions and AEs review  as recorded in Memory Aid as well as asked 
for by PI (or designee). The highest temperature written in the Memory Aid  each day will 
be recorded to source document as peak temperature.  
d) Findings of PI or study staff that suggest inaccuracy of reported self -assessments will be 
clearly documented.  
e) Any topics or new information considered by PI to be important to continued informed 
consent will be shared with the participant . 
f) Blood samples (8 mL) will be obtained for safety laboratory tests ( Appendix I ). 
g) Study staff will instruct the participant  regar ding continued self -assessment and need to 
contact study staff (a) in follow -up of specific AEs, (b) if injection site changes worsen or 
do not resolve, (c) if systemic symptoms worsen or do not resolve, and ( d) if other AEs 
occur.  
h) The next visit is scheduled.  
5.2.6.  Visit 4 (Day 29 +14 days ) 
On Day 29 (plus 14 calendar days if necessary for participant  compliance), the participant  will 
return to study site and the following procedures occur:  
a) Obtain  interim medical history, including medication use.   
b) Vital signs  will be measured.  
c) AEs will be evaluated.  
d) A targeted  physical exam will be performed, if indicated.  
e) Urine pregnancy test will be performed . 
f) Blood samples  (30 mL) will be obtained for immunological assays (see Appendix I ). 
g) The participant  will be reminded to contact the study site with any new information about 
chronic illnesses, serious health events, and/or hospitalizations, and the Day 85 follow -up 
contact information will be provided. Every effort should be made to adhere to the protocol 
windows.   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 45 of 106 5.2.7.  Visit 5 (Day 85 +14 days ) 
On Day 85 (plus 14 calendar days if necessary for participant  compliance), the participant  will 
return to study site and the following procedures occur:  
a) Interim medical history will be obta ined, including medication use.  
b) Vital signs will be measured.  
c) SAEs, if any will  be recorded and  evaluated.  
d) A targeted  physical exam will  be performed, if indicated.  
e) Urine pregnancy test will be performed . 
5.2.8.  Final Study Contact (Day 180 ±21 days)  
The participant will be contacted by telephone to assess any SAEs  that may have occurred .  
SAEs, if any will be recorded  and evaluated.  
5.3. Unscheduled Visits  
Unscheduled visits may be performed at participant ’s requests or direct ly by the  study site when 
the P I or staff member considers it necessary for diagnosis and/or management of a finding or 
AE. All unscheduled visits will be documented in participants’ study records and on applicable 
case report forms.  
5.4. Early Termination  
If a participant  withdraws from the  study for any reason prior to the planned study duration, every 
attempt is made to complete a termination visit to include the following.  
a) Report of local and systemic  reactogenicity and AEs are reviewed by PI (or designee).  
b) Vital signs are obtained.  
c) Specimens are obtained for chemistry, hematology and immunogenicity analysis if 
withdrawal occurs prior to  schedule  laboratory testing.  
d) Memory Aid  information is reviewed with the participant  in detail by site staff, if in use since 
the last visit.  
e) Injecti on site examination and a targeted physical examination are performed (if 
indicated).  
5.5. Procedure Methods  
Study procedures are performed and recorded in source documents as outlined in the Schedule 
of Events and according to the following subsections.  
5.5.1.  Vital Signs  
 Temperature in degrees Fahrenheit  (recorded to the nearest 0.1 degree) will be measured 
by oral thermometer .  
 Blood pressure in mm of mercury and heart rate in beats per minute  will be measured by 
automated device or manually.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 46 of 106 5.5.2.  Height and Weight  
 Height will be  measured in cm and recorded to the nearest 0.1 cm.  
 Weight will be  measured in kg and recorded to the nearest 0.1 kg.  
5.5.3.  Physical Examination  
Full physical examination will include assessment of vital signs, head, eyes, ears, nose, 
oropharynx,  neck, chest (auscultation), heart (auscultation), back, abdomen (auscultation and 
palpation), musculoskeletal, skin (especially injection site), and neurological. Not included are 
breast, genital or anorectal examinations.  
5.5.4.  Medical History  
 A comprehensive medical history will be collected at screening including, history of any 
vaccination in the last 30 days and ever received vaccination against Neisseria 
meningitidis , tetanus and diphtheria containing vaccines , current  medicat ion and history 
of any chronic or recurrent medical and psychiatric conditions.   
 An interim medical history will consist of inquiring regarding changes (healthcare events, 
signs, symptoms and changes in use of prescription or nonprescription drugs or herbal 
preparations) since the last medical history discussion.  
5.5.5.  Injection Site Examination  
Injection site assessment will be done by trained study personnel. Local reactions will be graded 
according to the toxicity grading scale in Appendix II.  
 Erythema/redness will be examined under standardized lighting conditions and measured. 
Severity of the reaction will be determined by staff on the basis of the severity  grading 
table (Appendix II).  
 Swelling /induration will be examined by palpation and vis ual inspection under 
standardized lighting conditions; the examiner may temporarily mark skin at margins of 
visible swelling/induration, then measure maximum diameter (as per Appendi x II).  
 Pain will be assessed by (a) inquiring as to whether there is sign ificant discomfort at rest  
and/or (b) whether movement of the injection site causes discomfort , impacts limb 
movement or daily activity (Appendix II).   
5.5.6.  Assessment of Reactogenicity  
The following parameters for reactogenicity will be assessed during the seven  days following 
vaccination.  
Local reactogenicity  
 Pain  
 Erythema / redness  
 Swelling / induration  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 47 of 106 Systemic reactogenicity  
 Fever (based on oral temperature)  
 Headache  
 Fatigue /malaise  
 Joint pain (arthralgia)  
 Muscle pain (myalgia ) 
 Diarrhea  
 Anorexia  
 Chills  
 Vomiting  
5.5.7.  Concomitant Therapy  
Other medications that are considered necessary for participant ’s welfare and that will not 
interfere with the vaccine may be given at the discretion of the investigator. At each study visit, 
the investigator/designee should ask the participant s about concomitant medication.  
Any of the medication taken at any time du ring the period starting 30 days before the first study 
vaccination and ending four weeks after the final study  vaccination must be captured with trade 
name and/or generic name, indication, start and end dates.  
The following drug/vaccines should not be tak en during study participation:  
1. Any investigational or non -registered drug or vaccine within 30 days prior to administration 
of study vaccines as well as during the entire study participation.  
2. Chronic administration (defined as more than 14 days) of immunosuppressant or other 
immune -modifying agents during the vaccine period. For corticosteroids, this means 
prednisone or equivalent  0.5 mg/kg/day. Topical or inhalable steroids will be allowed.  
3. Administration of routinely recommended licensed vaccine within 28 days post vaccination .  
4. Administration of immunoglobulin and/or any blood products during the study period.  
5. Prophylactic  antipyretics  or analgesics  to prevent fever or pain for seven  days p ost 
vaccination . 
5.5.8.  Clinical Laboratory Testing  
Laboratory evaluations for screening (hematology, chemistry, testing for HIV, Hepatitis B and C, 
and, for women of childbearing potential, pregnancy tests) and safety monitoring (hematology, 
chemistry and pregnancy tests for women of child bearing potential) are detailed in Appendix I, 
Schedule of Events.  
5.5.9.  Early Termination from Study  
An enrolled/vaccinated participant  may be terminated from the study for any of these reasons :  
a) Participant  withdraws consent.  
b) The participant  fails to comply with the study requirements so as to cause harm to 
him/herself or seriously interfere with the validity of the study results.  
c) Sponsor terminates the study.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 48 of 106 5.5.10.  Contraception and Pregnancy  
Contraception status is assessed and do cumented prior to enrollment and study vaccination  for 
female participants who are of childbearing potential. Prior to enrollment and at vaccination  visit, staff 
will ask participants to verbally confirm their use of adequate contraception methods if they are able 
to become pregnant. Adequate methods of contraception include double barrier contraception, 
hormonal birth control, IUD, or surgical sterility. If a participant  becomes pregna nt following 
vaccination , she will be encouraged to complete remaining visits and study procedures unless 
medically contraindicated. Any participant who becomes pregnant during the period between first 
vaccination and Day 180 will continue to be followed f or pregnancy outcome, if possible.  
6. LABORATORY EVALUATIO NS 
Blood samples will be obtained to examine vaccine safety and immunogenicity.  
6.1. Sample Collection , Distribution and Storage  
Samples to evaluate vaccine safety will  be obtained  at the clinical trial site and transported to the 
site’s designated laboratory  for clinical testing . Research specimens collected for the 
immunogenicity time points will be separated into aliquots by the site’s research  laboratory or 
study laboratory as per study specific process and sent to the contract laboratories. Samples will 
be stored properly in controlled -temperature refrigerators/freezers. Backup generators are 
available for proper sample storage.  
6.2. Safety Clinica l Laboratory Assays  
Protocol mandated screening and clinical safety laboratory tests will be conducted in real time  as 
per Schedule of Events (Appendix I).The clinical laboratory must maintain proper accreditation 
and subscribes to a proficiency testing pr ogram.  
Laboratory results will be reviewed promptly by the PI or designee.  Participants will be notified of 
any clinically significant abnormalities.  If clinically significant abnormalities are identified during 
screening, participant s will be referred to  their primary health provider or appropriate medical 
center. If identified during the study, participants may be asked to return to the study site for further 
evaluation, including clinical evaluation and repeat laboratory testing as warranted.  
6.3. Immunologi cal Assays  
The immunological assays to be performed are:  
Immunogenicity testing for Meningococcal Polysaccharide A, C, Y, W , and X specific antibodies 
using rSBA assay will be performed on sera collected at baseline ( Day 1) and 28 days post 
vaccination. Th e rSBA assay will be conducted at Vaccine Evaluation Unit at Public Health 
England (PHE) in Manchester UK. Additional immunogenicity assays may be performed by 
research laboratories to further evaluate post -vaccination  immune responses . These exploratory 
analyses may be done on a sub -sample of participant s’ sera, if remaining specimen volume is 
adequate . 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 49 of 106 6.4. Assay Qualification , Standardization and Validation  
The PHE rSBA assay for serogroups  A, C, Y, and W is a validated assay.  Samples from this study 
will be used for the validation of the PHE rSBA assay for serogroup X . 
6.5. Biohazard Containment  
As transmission of blood -borne pathogens can occur through contact with contaminated needles, 
blood, and blood products, appropriate blood  and secretion precautions will be employed by all 
personnel in the drawing of blood and shipping and handling of all specimens for this study, as 
recommended by the Centers for Diseases Control and Prevent ( CDC ). All biological specimens 
will be transport ed using packaging mandated by 42 CFR Part 72. All dangerous goods materials, 
including diagnostic specimens and infectious substances, must be transported according to 
instructions detailed in the International Air Transport Association (IATA) Dangerous G oods 
Regulations.  
Biohazardous waste will be contained according to institutional, transportation/carrier, and all 
other applicable regulations.  
7. STATISTICAL DESIGN A ND ANALYSIS  
7.1. Overview and General Design  
This study is a Phase 1  double blinded  randomized,  contro lled clinical trial to assess the safety 
and immunogenicity of the adjuvanted and non -adjuvanted  formulation of polyvalent conjugate 
vaccine composed of serogroups A, C, Y, W , and X Neisseria meningitidis  capsular 
polysaccharides  (MCV -5). The primary  objective is to evaluate the safety of adjuvanted and non -
adjuvanted formulations of MCV -5 vaccine. The secondary objective  is to assess the immune 
response of adjuvanted and non -adjuvanted formulations of MCV -5 vaccine.  
The primary hypothesis of safety w ill be fulfilled if no participants develop a vaccine related SAE 
and the vaccine is well  tolerated. The second hypothesis of immunogenicity will be fulfilled if the 
two formulations of MCV -5 induce immune response as measured by rSBA to all five serogroup s 
of the vaccines.  
A detailed statistical analysis plan for preparation of the final study report will be created and 
made final prior to database lock and unblinding.  All statistical analyses will be performed  using 
SAS® software Version 9. 3 or later.  
Medical history and AEs will be coded using the current version of the Medical Dictionary for 
Regulatory Activities ( MedDRA ) dictionary.  The frequency count and percentage of participants 
will be summarized according to the coded terms of system  organ clas s and preferred term.  
Participant -wise data listing will be provided.  
7.2. Randomization and Blinding Procedures  
The randomization scheme will be generated and maintained by the Statistical and Data 
Management Group (SDMG) at the Emmes Corporation, Rockville, MD. Participants  will be 
enrolled into the study online and randomized using the enrollment module of the Emmes 
Corporation’s AdvantageEDCSM electronic data capture system . Each participant  enrolled into the 
trial will be assigned a treatment code after demographic and eligibility data have been entered 
into the system.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 50 of 106 The pharmacist with primary responsibility for dispensing study products is charged with 
maintaining security  of the treatment assignments.  
7.3. Objectives and Endpoints  
7.3.1.  Primary  
Objective: To e valuate the safety  of adjuvanted and non -adjuvanted formulations of MCV -5 
vaccine  in healthy adults . 
Endpoints:  
Summaries by product received including the number and percentage of participants 
experiencing:  
 immediate AEs within 60 minutes post-vaccination ; 
 solicited local or systemic post vaccination  reactogenicity reactions within seven  days 
following vaccination ( Days one through seven ); 
 any SAE within six months following vaccination;  
 any AE within 28 days following vaccination;  
 any Gr ade 2 or greater solicited local or systemic post vaccination  reactions within seven  
days following vaccination;  
 any Grade 2 or greater unsolicited AE within 28 days following vaccination;  
 any unsolicited AE within 28 days following vaccination judged to be related to study 
product; and  
 any Grade 2 or greater unsolicited AE within 28 days following vaccination judged to be 
related to study product.  
7.3.2.  Secondary  
Objective:  To assess  the immune response of adjuvanted and non -adjuvanted formulations of 
MCV -5 vaccine in healthy adults  
Endpoints:  
 The percentage of participants who show a seroconversion for Meningococcal 
Polysaccharide A, C, Y, W , and X specific antibodies, i.e. a ≥4 -fold increase in post -
immunization rSBA titer with respect to pre -immunization rSBA titer, at 28 days after a 
single vaccine dose.  
 The percentage of participants who show a post -immunization seroprotection titer for 
Meningococcal Polysaccharide A, C, Y, W , and X specific antibodies defined as rSBA titer 
of 1:8 and 1:128 at 28 days after a single vaccine dose.  
 GMTs of Meningococcal Polysaccharide A, C, Y, W and X specific antibodies at 28 days 
after a single vaccine dos e, as measured by rSBA assay . 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 51 of 106 7.3.3.  Exploratory  
Immune response of adjuvanted  and non -adjuvanted formulations of MCV -5 may be assessed 
by other relevant assays, if remaining specimen volume is adequate .  
7.4. Sample Size Justification  
Since this study is a Phase 1 trial it is designed to provide preliminary safety and immunogenicity 
data that may support testing the study product in additional larger cohorts in adults and in age -
descending studies.  
With 20 vaccine recipients per vaccine group, this study ’s design allows a greater than 90% 
chance of observing an AE that has an 11% chance of occurrence. Conversely, if no AEs are 
observed in 20 vaccine recipients, the study will be able to rule out AEs occurring at a rate of 
approximately 14% based on the upper bounds o f the one -sided 95% Confidence Interval.  
No formal statistical hypothesis testing is planned for this first time in human Phase 1  study whose 
objectives are aimed to descriptively evaluate the safety and immunogenicity profile of the study 
vaccines  
7.5. Analyt ical Methodology  
7.5.1.  Analysis Population  
Definitions of analysis populations to be analyzed are:  
Enrolled Population  
All screened participants who provide informed consent, regardless of the participant’s 
randomization and treatment status in the trial.  
Full Analysis population  
All participants in the enrolled population who were randomized and received a study vaccination. 
All safety analyses will be performed using this population. Treatment groups for safety analysis 
will be assigned according to the actual treatment received at Day 1.  
Per Protocol population  
All participants in the per protocol population who are assigned the study vaccination with no 
major protocol violations that are determined to potentially interfere with the immunogenicity 
asse ssment of the study vaccine. This population will serve as the primary analysis population for 
the immunogenicity endpoints.  
The criteria for exclusion of participants from the Per Protocol Population will be established 
before breaking the blind and will be based on the blinded review of protocol violations.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 52 of 106 7.5.2.  Statistical Method  
When the use of descriptive statistics to assess group characteristics or differences is required, 
the following methods will be used: for categorical variables, the number and percent of 
participants in each category; for continuous variables, the mean, m edian, standard deviation, 
quartiles and range (minimum, maximum).  
In general all missing data will be  treated as missing completely at random and no imputation will 
be performed except for the safety endpoints as described below. Non -analyzable data (e.g ., due 
to major protocol violations) will be documented in the deviations.  
If some safety data are available for a subject in the safety population but respective secondary 
endpoint related data are missing then the subject will be included in the safety analysis and data 
will be treated as follows for immediate AEs, solicited AEs, unsolicited AEs and SAEs.  
1. If Severity is missing for any AE then it will be considered as  an AE of maximum severity 
(Grade 3) “Severe” unless it’s captured as SAE .  
2. If “Relationship” is missing then it will be considered as “Related” to the vaccine administered.  
3. If, for Start date, the day of event/condition is missing due to  any adverse event then it will be 
imputed as the date of last dose of study vaccine.  
4. If, for Start date, the day and month of an adverse event is missing , then it will be imputed as 
the date of first dose of study vaccine.  
5. If the Stop date of an adverse event is missing then it will be treated as ongoing.  
Analysis of Primary Safety Obj ective  
The p rimary aim of the study is to assess the safety of the study vaccine.  All safety data (solicited 
local and systemic reactions and unsolicited AEs and SAEs) collected after participants are 
exposed to the study product will be included in the primary analys is of safety.   
To assess safety, the number and percentage of participants experiencing at least one AE, and 
the number and percentage of participants experiencing each specific AE, categorized by body 
system and preferred term, will be tabulated by produc t received along with their corresponding 
two-sided exact 95% confidence intervals.  
Fisher’s exact test will be used to compare the proportion of participants with solicited local and  
systemic reactogenicity events between the MCV -5 group and the Menactra® Group. The primary 
purpose of statistical comparisons is to screen out potential solicited reactogenicity events that 
need further clinical evaluation. Therefore, they are not considered formal statistical hypothesis 
tests and it is acknowledged that there will be inflated Type I error s (i.e. inflated false statistical 
significances) from performing multiple unadjusted comparisons.  
Changes in clinical laboratory values from baseline to end of treatment/follow -up will be analyzed 
descriptively.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 53 of 106 To facil itate the planning of the follow -up trial, analysis of unblinded primary safety data up to Visit 
4 (Day 29) by treatment groups will be made available to the Sponsor after all participants have 
completed this visit and their data have been cleaned and veri fied.  
Analysis of Secondary and Exploratory Immunogenicity Objective  
The percentage of participants with a 4 -fold response in rSBA titer against serogroups A, C, W, 
Y and X will be defined as:  
 For participants with a pre -vaccination rSBA titer <8, a post -vaccination titer of ≥32;  
 For participants with a pre -vaccination rSBA titer ≥8, an increase in rSBA titer of at least 4 
times the pre -vaccination titer.  
For seroresponse rate endpoints, two -sided 95% exact confidence intervals (C Is) for each of the 
propor tions will be provided. Two -sided exact 95% CIs for the three  pair-wise proportion 
differences between the three  treatment groups will be computed using the unconditional exact 
method proposed by Chan and Zhang (1999) or another appropriate method.  
For the  purpose of determining GMT antibody titer below 1:8 will be given an arbitrary value of 
half of the assay’s cut -off (4) . GMT will be calculated as: GMT = antilog (mean loge -x]) where x is 
the assay result and e is the natural logarithm. GMTs will be summa rized by treatment group and 
by visit with corresponding two -sided 95% CIs based on the t-distribution to provide population 
estimates. Two -sided 95% CIs for the ratios of GMTs betwee n treatment groups will be 
constructed using  the log normal distribution.  The log values will be used to construct a CI using 
the t-distribution for the mean difference between three  pair-wise treatment groups. The mean 
difference and the corresponding CI limits will then be exponentiated to obtain the GMT ratio and 
the corresp onding CI. If the values deviate from  a log normal distribution, a nonparametric method 
may be used for the analysis of GMT.  
Due to the hypothesis generating nature of multiple statistical comparisons for immunogenicity 
associated with multiple endpoints for this early phase first study  in human subjects , all 
estimations will be carried out using a two -sided 5% Type I error rate without an adjustment for 
multiple comparisons.  
8. SAFETY ASSESSMENT AN D REPORTING  
This section defines the types of safety events that should be reported and outlines the 
procedures for appropriately collecting, grading, recording and reporting them.  
8.1. Safety Events  
All safety events observed under this protocol are reported through the AdvantageEDC data 
system throughout the study. Sa fety events related to vaccine reactogenicity are collected on 
study -specific forms. Reactogenicity will be collected through the visit on Day 7, if a solicited sign 
or symptom has started during the seven  days post -vaccination and continues it will contin ue to 
be reported as a reactogenicity symptom. Only when the reactogenicity event is considered an 
SAE, as defined below, will it be reported on an AE/SAE form set, in addition to the reactogenicity 
form.  Any symptom starting after seven  days post -vaccinat ion will be recorded as an AE. All other 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 54 of 106 safety events that meet the definition of an AE or SAE that occur throughout the study are reported 
on the AE/ SAE form set. AE's will be collected through study visit Day 28. SAEs will be assessed 
through Day 180 and will be reported on the AE/ SAE form set.  
8.2. Reporting Period  
Safety events are reported from the time of the vaccination  through completion of the study at 6 
months as  described  above.  
8.3. Definitions  
8.3.1.  Adverse Event (AE)  
An adverse event is any untoward medi cal occurrence in humans, whether or not considered 
vaccine related, that occurs after the vaccination  during the conduct of a clinical trial. Any change 
from baseline assessment of clinical status, ECGs, routine laboratory tests, X-rays, physical 
examinations, etc., that is considered clinically significant by the PI is considered an AE.  
Suspected adverse drug reaction is any AE for which there is a reasonable possibility that the 
vaccine caused the AE. A reasonable possibility imp lies that there is evidence  to suggest  that the 
study product caused the event.  
Adverse reaction is any AE caused by the vaccine.  
8.3.2.  Serious Adverse Events (Defined as Serious Adverse Events, Serious 
Suspected  Adverse Reactions or Serious Adverse Reactions)  
An SAE, including a serious suspected adverse reaction or serious adverse reaction as 
determined by the PI or the Sponsor, is any event that results in any of the following outcomes:  
1. Death . 
2. Life-threatening AE (Life -threatening means that the study partici pant was, in the opinion 
of the PI or Sponsor, at immediate risk of death from the event as it occurred.)  
3. Inpatient hospitalization or prolongation of existing hospitalization . 
4. Persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions .  
5. Congenital abnormality or birth defect . 
6. Important medical event that may not result in one of the above outcomes but may 
jeopardize the health of the study participant  or require medical or surgical intervention to 
preven t one of the outcomes listed in the above definition of serious event .  
8.3.3.  Unexpected Adverse Event  
An AE is “unexpected” when its nature (specificity) or severity is not consistent with applicable 
product information, such as safety information provided in t he Investigators’ Brochure (IB), the 
investigational plan or the protocol.   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 55 of 106 8.4. Severity  Grading  
The study site assigns severity  grades to indicate the severity of adverse events  and reactions . 
The severity  grading criteria provided in Appendix I I grade AEs from Mild ( Grade 1) to Life 
Threatening ( Grade 4). All AEs leading to death are Grade 5 events. AEs are graded with the 
worst severity grade during the illness/symptoms. AE severity will be graded using the attached 
grading scale (Appendix II)  based on the  Division of AIDS (DAIDS) Table for Grading the Severity 
of Adult and Pediatric Adverse Events , version 2.0, November 2014, of the US National Institute 
of Health.  
8.5. Guidelines for Determining Causality of an Adverse Event  
The PI should consider t he following question when assessing causality of an AE to study product:  
Is there a reasonable possibility that the study product caused the event?  
Reasonable possibility implies there is evidence  to suggest that the study product caused the 
reported eve nt. An affirmative answer designates the event as a suspected adverse reaction , and 
the AE is considered “related”.  If the answer is no, then the AE is considered “unrelated” . 
The causality assessment is made on the basis of the available information at th e reporting time 
point. Assessment of causality can change according to follow -up information.  
8.6. Assessment of Outcome of Adverse Event  
The o utcome of adverse event will be assessed as at the time of last observation  as per the 
followi ng categories :  
 Recovered/resolved without sequelae  
 Recovered/resolved with sequelae  
 Ongoing  at the end of the study  
 Death  
 Unknown.  The outcome of the AE is not known  
8.7. Adverse Event Identification, Resolution and Reporting  
To improve the quality and precision of acquired AE data, the PI should observe the following 
guidelines:  
 Whenever possible, use recognized medical terms when recording AEs on the AE CRF.  
Do not use colloquialisms and/or abbreviations.  
 If known, record the diagnosis (i.e., disease or syndrome) rather tha n component signs, 
symptoms and laboratory values on the AE CRF (e.g., record congestive heart failure 
rather than dyspnea, rales, and cyanosis).  However, signs and symptoms that are 
considered unrelated to an encountered syndrome or disease should be reco rded as 
individual AEs on the CRF (e.g., if congestive heart failure and severe headache are 
observed at the same time, each event should be recorded as an individual AE).  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 56 of 106  AEs occurring secondary to other events (e.g., sequelae) should be identified by the  
primary cause. A “primary” AE, if clearly identifiable, generally represents the most 
accurate clinical term to record on the AE CRF.  If a primary serious AE (SAE) is recorded 
on an SAE CRF, events occurring secondary to the primary event should be descri bed in 
the narrative description of the case.  
 For example:  
Orthostatic 
hypotension   Fainting and 
fall to floor   Head 
trauma   Neck pain  
The primary AE is orthostatic hypotension.  
 Grade 2 or higher abnormal laboratory test results will be  reported  as AEs and assessed 
for severity according to severity grading criteria provided in Appendix II and causality 
(related or unrelated)  to the study product.  Grade 1 abnormal laboratory test results will 
be entered as AEs if the s ite PI determines them to be  clinically significant.  
 Death is an outcome of an event.  The event that resulted in the death should be recorded 
and reported on the SAE CRF.  
 For hospitalizations for surgical or diagnostic procedures, the illness leading to the surgical 
or diagnostic pro cedure should be recorded as the SAE, not the procedure itself.  The 
procedure should be captured in the case narrative as part of the action taken in response 
to the illness.  
 Pregnancies that occur in study participants are not considered AEs and will be r ecorded 
on a separate Pregnancy CRF. Pregnancy outcomes that include stillbirth and any 
congenital anomalies must be reported as SAEs.  
AEs may be discovered through any of these methods.  
 Observing the participant . 
 Questioning the participant , which should be done in an objective manner.  
 Receiving an unsolicited complaint from the participant . 
 Review of medical records/source documents.  
Each participant  will have a scheduled observation following vaccination , including a symptom -
directed physical examination , if indicated. They will be monitored in -house for 60 minutes  after 
vaccination . On Days 1 to 7 after vaccination , participants will be instructed to assess and record 
daily in a participant  memory aid any signs and symptoms at the injection site, as well  as systemic 
signs and symptoms . Follow -up visits will be conducted seven  days after vaccination , including 
directed assessment, safety tests and verification of memory aid notes. They will be instructed to 
call the study team if they observe significant i njection site or systemic signs or symptoms, and 
then to continue monitoring and reporting their condition. All participants will be followed for safety 
for six months after the vaccination . 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 57 of 106 8.7.1.  AE Resolution  
All reported AEs should be followed until resolution or stabilization, or until the participant’s 
participation in the study ends.  Participants who have an ongoing study product -related SAE at 
study completion or at discontinuation from the study will be f ollowed by the PI or his designee 
until the event is resolved or determined to be irreversible, chronic, or stable by the PI.  
8.7.2.  General Recording and Reporting Procedures  
A multi -page AE/SAE form set will be used allowing all AEs to be submitted through a si ngle 
reporting mechanism. SAEs will require additional information reported on additional pages within 
the Internet data entry system. As appropriate or per request of the Emmes  medical monitor or 
Sponsor medical officer , source documents (e.g., hospitaliz ation discharge summaries) may be 
uploaded to the AE/SAE form set as well. The PI will treat  or refer, as appropriate,  participants 
experiencing AEs and observe them at suitable intervals until their symptoms resolve or their 
status stabilizes.  
8.7.3.  SAE Recordi ng and Reporting Procedures  
SAEs will be recorded on the AE CRF. The site is obligated to report SAEs to the Emmes  
Coordinating Center  within 24 hours of the site’s knowledge of the event.  The E mmes  
Coordinating Center  will in turn pass on that information  to Sponsor  and SIIPL .  
The following attributes will be assigned by the PI or assignment by designee will undergo 
documented review by the PI:  
 Description  
 Date of onset and resolution (if known when reported)  
 Severity  
 Assessment of relatedness to test article  
 Action taken  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 58 of 106 8.7.4.  Site Reporting of Events  
Figure 3: Reporting Decisions for Adverse Events  
 
 Notify the PI.  
 Complete and transmit an AE Form through the Internet data entry system. Information 
regarding a SAE report must be recorded in the participant’s medical chart and entered in 
the Internet data entry sy stem.  
 SAE follow -up reports should include hospital admittance notes, hospital discharge 
summary, clinical notes, resolution date, treatment, and any other pertinent information 
regarding the event. If not immediately available, reporting should not be del ayed to 
provide these documents.  
 In the event of a death, the SAE Form must be completed and transmitted along with other 
supporting data (e.g., death certificate, medical notes).  
  No Yes Safety Event requiring AE Form Submission : 
All adverse events and all serious adverse events  
SAE?  Expedited Reporting  
(Within 24 hours)  
Use the  Serious Adverse Event Form  
Submit to Emmes Coordinating Center 
(also notify ethics board/IRB  as per 
ethics board/ IRB guidelines ) Standard Reporting  
(Within 5  to 7 days)  
Use the Adverse Event Form  and 
other CRFs  
Submit to Emmes Coordinating Center  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 59 of 106 8.8. Serious Adverse Event Notification  
8.8.1.  Notifications and Review  
The PI will provide the Emmes Coordinating Center with data for all SAEs, as defined per the 
protocol, on a timely manner  by entering the information in AdvantageEDC.  The Emmes 
Coordinating Center is responsible for notifying the Sponsor and will do so sim ultaneously with 
the reporting to the clinical database. Notification of reported events will be generated at the time 
of entry into the data system, and all SAEs will be reviewed promptly by the Emmes medical 
monitor within the data system. As noted above , this notification should be within 24 hours of site 
awareness of the event. Site personnel will be trained in reporting AEs and SAEs.  
The Emmes medical monitor will review all unanticipated events involving risk to participants or 
others, SAEs and all participant  deaths associated with the protocol and will provide a written 
report. At a minimum, the Emmes medical monitor must comment on the outcomes of the event 
or problem and, in case of an SAE or death, comment on the relationship to participation in the 
study. The Emmes medical monitor must also indicate whether he/she concurs with the details of 
the report provided by the PI.  
Summary review of all reported AEs and SAEs will be compiled on a weekly basis to identify any 
safety trends. Review of safety  laboratory tests will also be conducted on a weekly basis.  
8.8.2.  Expedited Reporting  
The Emmes Coordinating Center will be responsible for expedited IND Safety Reports and IND 
Annual reports to the FDA.  
When expedited reports as defined below are required, the  cover memorandum, MedWatch Form 
FDA 3500A, and any pertinent attachments will be processed by the Emmes  medical monitor and 
a copy of the completed report will be submitted by fax or courier delivery before the regulatory 
reporting deadline, to the follow ing persons:  
 FDA medical officer as appropriate (submitted as an amendment to the applicable 
IND) 
 PI (who is responsible for forwarding the report to the local/central IRB)  
 Safety Review Committee members  
If relevant follow -up information becomes available, the Emmes medical monitor will be 
responsible for obtaining and reviewing details from the site. A follow -up MedWatch form will be 
completed and forwarded to all parties that received the earlier SAE rep ort. A copy of the safety 
sections for annual FDA reports will be forwarded to PATH .  
Suspected adverse reactions that are serious and unexpected will be reported to the FDA within 
15 days, or for deaths and life threatening events that are both suspected adverse reactions and 
unexpected, within 7 days (per 21 CFR 312.32).  The IND Safety Report will be unblinded to 
treatment allocation and determination of  relationship to study product based on the assessment 
of the sponsor.   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 60 of 106 Subsequent review by the FDA, the SRC, IRB, or the Sponsor may suspend further study product 
administration or procedures. The FDA and the study Sponsor  with consultation with the SRC 
retain the authority to suspend additional enrollment for the entire stu dy as applicable.  
8.8.3.  Notifying the Safety Review  Committee  
The Emmes Coordinating Center will provide the SRC with listings of all SAEs on an ongoing 
basis.  Furthermore, the SRC will be informed of expedited reports of SAEs.  
8.8.4.  Notifying the Institutional Review  Board  
The PI will ensure the timely dissemination of required AE information, including expedited 
reports, to the IRB in accordance with applicable local regulations and guidelines. The PI is 
responsible for submitting the IND S afety Report (initial and f ollow up SAE reports) or other safety 
information (e.g., revised IB) to the site’s IRB and for retaining a copy in the site’s study file.  
University of Maryland, Baltimore (UMB) IRB  
Using the same criteria above, any qualifying SAE will be reported to the UMB IRB, as a reportable 
new information event and within five business days. The contact information for the UMB IRB is 
as follows:  
University of Maryland, Baltimore  
Human Research Protections Office  
Lexington Building  
620 West Lexington Street, Second Fl oor 
Baltimore, MD 21201  
410-706-5037  
9. SAFETY MONITORING  
Extensive safety monitoring will be provided for this protocol. The PI and/or designated site staff 
will be responsible for continuous close safety monitoring of all study participants and for alerting 
the Sponsor if unexpected concerns arise or pause criteria are met.  
9.1. Safety Review Committee  
A Safety Review Committee, comprised of the PI,  a medical expert with experience in vaccine 
pharmacovigilance not involved with the study , the Emmes  medical monitor, SIIPL  and PATH  
medical officer will monitor safety throughout the duration of the study.  The Emmes  study 
statistician with assistance of the data management staff will prepare safety reports as needed 
for SRC discussions.  During the vaccination period the SRC will review weekly  the safety data . 
At any time during the study, the E mmes  Coordinating Center  will notify the SRC of ad hoc review 
if pause  criteria may have been  met. The SRC reviews will be summarized with consensus 
recommend ations to the study Sponsor as to whether there are safety concerns and whether the 
study should continue without change, be modified, or be stopped . The SRC may request review 
of unblinded safety data by the  pharm acovigilance expert  in its deliberation.  SRC consensus 
recommendations regarding modifying or stopping further enrolment  may involve Sponsor 
consultation with the local regulatory authorit y. 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 61 of 106 The SRC members must be satisfied that the  timelines, completeness, and accuracy of the data 
submitted to them for review are sufficient. Items reviewed  by the SRC may include: study 
participant  demographic information; interim/cumulative data for evidence of study -related 
AEs;  data quality, completeness, and timeliness ; and factors external to the study, such  as 
scientific or therapeutic developments that may impact participant  safety or the ethics of the study . 
If at any time, a decision is made to discontinue administration of study product in all participants , 
expeditious notification will be provided by the sponsor to the US FDA and by the PI  to the site 
IRB.  
9.2. Study Pause Rule  
The following study pause  rules will automatically pause or halt further vaccinations . However 
participant s already enrolled will continued to be followed for safety during the pause.  These 
pause  rules refer to suspected adverse reactions  and will be triggered automatically if any of the 
event described below are met during the conduct of the study:  
 One or more participant s experience a serious adverse reaction . 
 One or more participant s experience a Grade 4 injection site reaction . 
 Two or more participants  experience the same Grade 3 injection site reaction . 
 Two or more participants  with the same severe ( Grade 3) systemic reactogenicity signs or 
symptoms, within seven days following vaccination . 
 Two or more participants  experience the same vaccine -related Grade 3 or higher clinical 
(including fever) or laboratory abnormality . 
9.2.1.  Pause  Procedure  
 The SRC will be notified by the E mmes  Coordinating Center and convene ad hoc review 
if pause criteria may have been met.  
 At scheduled study review, the SRC may also identify adverse events that could  potentially 
qualify as pause  criteria.  
 If the PI (or designee), the Emmes  medical monitor or any member of the SRC identifies 
that a  pause  criterion may have been met or propose the study be paused  on a 
discretionary basis, all vaccinations  and enrollment will be suspended. The SRC will be 
notified and will expeditiously  (within 48 hours)  convene to review all available, relevant 
information . The SRC may request review of unblinded safety data by the 
pharma covigilance expert , The SRC reviews will be summarized with  consensus  
recommendations to the study Sponsor as to whether there are safety concerns and 
whether the study should continue withou t change, be modified, or be stopped . 
 If at any time, a decision is made to discontinue administration of study product in all 
participant s, expeditious notification will be provided by the Sponsor to the US FDA and 
by the PI to the IRB within 48 hours . 
 If the Sponsor re -starts the study after SRC review and recommendation, enrollment and 
vaccination may resume.   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 62 of 106 10. DATA MANAGEMENT  
The PI is responsible for ensuring the accuracy, completeness, and timeliness of the data 
reported.  Data collection is the responsibility of the clinical trial staff at the study site under the 
supervision of the study PI.  The Emmes Corporation is responsible for data management 
activities, including quality review, analysis, and reporting of the study data according to  Standa rd 
Operations Procedure  (SOP ). 
10.1.  Case Report Form Development and Completion  
Electronic Data Capture will be the method of data collection in this study. The electronic Case 
Report Forms ( eCRFs ) will be developed by the Emmes Corporation and approved by SIIPL  and 
PATH . Clinical data (including AEs, concomitant medications, and reactogenicity data) and 
clinical laboratory data will be entered into the 21 CFR Part 11 -compliant Internet Data Entry 
System (IDES) provided by The Emmes Corporation. The data sys tem includes password 
protection and internal quality checks, such as automatic range checks, to identify data that 
appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the 
source documents.  
Data for each participant  will be recorded in the eCRF. It is the PI’s responsibility to ensure the 
accuracy, completeness, legibility, and timeliness of the data reported in the participant’s eCRF 
and any supporting documentation. All source documents should be completed in a nea t, legible 
manner to ensure accurate interpretation of data. Source documentation supporting the eCRF 
data should indicate the participant’s participation in the study and should document the dates 
and details of study procedures, AEs and the participant’s  status. The PI/institution will maintain 
all information in the eCRFs and all source documents that support the data collected from each 
participant . 
The PI or designated representative should complete the eCRFs as soon as possible but within 
three  days after information is collected. Completed eCRFs must be submitted for each screened 
participant  who signs the study -specific ICF.  The eCRFs will not be completed for participants 
who do not sign the study specific ICF.  The PI will retain all essential docu ments . 
10.2.  Details of Data Management  
A Data Management Handbook (DMH) will be written by The Emmes Corporation and contain all 
study -specific requirements.   
10.2.1.  Coding  
The PI is responsible for ensuring the accuracy, completeness, and timeliness of the data 
repor ted. Data collection is the responsibility of the clinical trial staff at the study site under the 
supervision of the study PI.  The Emmes Corporation is responsible for data management 
activities, including quality review, analysis, and reporting of the st udy data according to SOPs.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 63 of 106 10.2.2.  Data Validation  
The Emmes Corporation will inspect the data entered into the database for completeness and 
consistency.   
10.2.3.  Source Data Verification  
For source data verification (SDV), the monitor (on behalf of the study Sponsor) m ust have direct 
access to source documents that support the data recorded, e.g., medical records, original 
laboratory records and ICFs. If source data are electronic, these data must be printed, signed and 
dated by the PI and stored in the participant’s study file. Clinical laboratory data will remain in 
study participant  records. Essential documents, including ICFs, must be filed and kept in the study 
files on an ongoing basis.  
10.2.4.  Definition of Source Data  
Source data are all information in original records o r certified copies of original records of clinical 
findings, observations, or other activities in a clinical study. Source data are contained in source 
documents.   
10.2.5.  Definition of Source Document  
Original source documents include data and records, e.g., hosp ital records, medical notes, 
laboratory notes, evaluation checklists, pharmacy dispensing records, records kept at the 
pharmacy and at the laboratory, documentation of shipments. Note that, for this protocol, the 
volunteer participant data collection tool (i.e., the Memory Aid) is not considered a source 
document.  Data reported in the eCRF derived from source documents should be consistent with 
the source documents or the discrepancies should be explained.  
10.3.  Database Locking Procedures  
 A final database lock f or the primary analysis will occur after all participants have 
completed all follow -up visits, a case -by-case review of the severity of any AEs has been 
performed and finalized, all data anomalies have been resolved and monitoring is 
complete.  
 Remaining i mmunology data will be maintained in a separate immunology database.  
10.4.  Record Archival  
The PI is responsible for retaining study records for a period of two years following the date that 
a marketing application is approved for the product or, if no applicat ion is to be filed or, if a file 
application is not approved, until two years after the investigation is discontinued and the FDA is 
notified. The Sponsor will be responsible for providing the site with date of vaccine approval or 
IND withdrawal.  
These rec ords are also to be maintained in compliance with IRB, state, and federal medical 
records retention requirements, whichever is longest. Storage of all trial -related documents will 
be such that confidentiality will be strictly maintained to the extent provi ded by federal, state, and 
local law.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 64 of 106 10.5.  Screen Failures  
If a participant  signs the study -specific ICF, but is not randomized because of non -eligibility (a 
screen failure), the reason for his/her non -eligibility should be entered in the medical 
records/notes/charts. Also, a screening log must be kept. Data from participants who fail 
screening will not be recorded in the eCRF, with the exception of demographic data and the 
reason for screen fail.   
10.6.  Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or site SOP 
requirements.  The nonc ompliance may be either on the part of the participant , the PI, or the study 
site staff.  As a result of deviations, corrective actions are to be developed by the site and 
implemented promptly.  
These practices are consistent with ICH E6:  
 Compliance with Pr otocol, Sections 4.5.1, 4.5.2, and 4.5.3 . 
 Quality Assurance and Quality Control, Section 5.1.1 . 
 Noncompliance, Sections 5.20.1 and 5.20.2.  
It is the responsibility of the site to exercise continuous vigilance to identify and report deviations 
within five working days after identification of the protocol deviation, or within five working days of 
the scheduled protocol -required activity. All deviations must be promptly reported to Emmes  and 
sponsor via the appropriate eCRF within the electronic data system.  
All deviations from the protocol must be addressed in study participant  source documents . 
Protocol deviations must be sent to UMB IRB per its guidelines. The site PI/study staff is 
responsible for knowing and adhering to UMB IRB’s requirements.  
11. STUDY MONIT ORING  
Sponsor monitoring responsibilities will be provided by The Emmes Corporation. A site initiation 
visit will be conducted prior to beginning the study, and monitoring will be conducted at initiation, 
during, and at closeout of the study by the study m onitor or designee.   
During the course of the study, the Emmes monitor will visit the clinical site at intervals to verify 
compliance to the protocol; check for completeness, accuracy, and consistency of the data and 
study product accountability; adherence  to CFR, and any additional regulations and requirements, 
including GCP, of the conduct of clinical research. The monitor should have access to participant  
medical records, study product accountability and other study -related records needed to verify 
the e ntries on the eCRFs.  
The PI and the monitor must agree to cooperate to ensure that any problems detected in the 
course of these monitoring visits, including eCRF completion and query resolution, are resolved 
in a predefined timeframe.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 65 of 106 To ensure the qualit y of clinical data across all participants at the site, a clinical data management 
review will be performed on volunteer data received at The Emmes Corporation. During this 
review, participant  data will be checked for consistency, omissions, and any appare nt 
discrepancies. In addition, the data will be reviewed for adherence to the protocol and GCP. To 
resolve any questions arising from the clinical data management review process, data queries 
and/or site notifications will be sent to the site for resolutio n prior to the site’s last monitoring close -
out visit.  
Essential documents must be filed in the site study file on an ongoing basis and available for 
review by the Emmes  monitor. Monitoring visits will be performed according to the Clinical 
Monitoring Plan . 
11.1.  Independent Auditing  
The SIIPL  or PATH representatives may audit the study to ensure that study procedures and data 
collected comply with the protocol and applicable SOPs at the clinical site and The Emmes 
Corporation, and that data are correct and compl ete. The PI will permit auditors (employees of 
the Sponsor or an external company designated by the Sponsor) to verify source data validation 
of the regularly monitored clinical study. The auditors will compare the entries in the eCRFs with 
the source data  and evaluate the study site for its adherence to the clinical study protocol and 
GCP guidelines and applicable regulatory requirements.  
11.2.  Regulatory Agency Auditing  
The PI must be aware that representatives from regulatory authorities or the IRB may wish to  
inspect the eCRFs and associated study records. The PI will notify the Sponsor within 24 hours 
following contact by a regulatory agency. The PI and study coordinator must make the relevant 
records available for inspection and will be available to respond to reasonable requests and audit 
queries made by authorized representatives of regulatory agencies. The PI will provide the 
Sponsor with copies of all correspondence that may affect the review of the current study or his 
qualification as an investigator in  clinical studies conducted by the Sponsor. The Sponsor will 
provide any needed assistance in responding to regulatory audits or correspondence.  
12. OBLIGATIONS AND ROLE S OF THE SPONSOR, PI  AND STUDY PERSONNEL  
This study will be conducted according to GCP and in accordance with all federal regulations 
regarding the protection of human participant s in research including US 21 CFR Part 50 and US 
21 CFR Part 312. The PI agrees to perform the research in strict acco rdance with this protocol, 
the International Co uncil for Harmonisation (ICH) Guideline for Good Clinical Practice (E6), as 
well as in conformity with any federal, state, or local regulations regarding the conduct of clinical 
studies.  
In addition, the PI mu st follow local and institutional requirements including, but not limited to, 
investigational product, clinical research, informed consent and IRB regulations. The Sponsor will 
provide notification to the PI of protocol and amendment approvals by regulator y authorities when 
applicable. Any modifications to the research protocol, the ICF, and/or the questionnaires or 
change in PI must be submitted to UMB IRB for review and approval prior to implementation. The 
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 66 of 106 PI may deviate from the protocol without prior a pproval only when the deviation is necessary to 
eliminate an apparent immediate hazard to the participant .  
The PI will notify UMB IRB of SAEs and protocol deviations according to UMB IRB requirements.  
Any deviation to the protocol that may have an effect on the safety or rights of the participant , or 
the integrity of the study, must be reported to the Sponsor by the PI as soon as the deviation is 
identified. In that event, the PI will notify the Emmes /Sponsor immediately by phone, notify UMB 
IRB, enter the deviation into the appropriate eCRF, and confirm notification to the Sponsor in 
writing within ten working days after the change is implemented.  All deviations will be noted in the 
continuing review re port to and UMB IRB , the annual report to the Sponsor, and in the final study 
report for and UMB IRB . 
Except where the PI's signature is specifically required, it is understood that the term "investigator" 
as used in this protocol and on the eCRFs refers t o the PI or appropriate study personnel that the 
PI designates to perform a certain duty. The PI is ultimately responsible for the conduct of all 
aspects of the study. Sub -investigators or other appropriate study personnel are eligible to sign 
for the PI o n designated eCRFs.  
The Emmes  medical monitor will be responsible for reviewing all serious and unexpected AEs 
and providing an unbiased written report of the event.  
13. ETHICAL CONSIDERATIO NS AND INFORMED CONS ENT 
13.1.  Informed Consent Process  
Before any study -related activities and in agreement with applicable regulatory requirements, the 
PI must ensure that the participant  is fully informed about the aims, procedures, potential risks, 
and potential benefits of the study. The participant  will be given the written, IRB approved ICF, 
allowed ample time to read the consent form, encouraged to ask questions about the study, have 
the questions answered and then be given time to decide if s/he would like to participate in the 
study. It will be emphasized that participatio n is voluntary, and that the participant  has the right to 
withdraw from the study at any time without prejudice.  
The PI or designee must obtain the participant’s voluntary, personally signed and dated ICF 
before any study -related procedures. The original, signed ICF must be kept in the site study file.  
13.2.  Risk/Benefit  
No benefits can be guaranteed to participants for their participation in this research study.  
Risks from Vaccine  
As with all injectable vaccines, appropriate medical treatment and supervision should always be 
readily available in case of a rare anaphylactic event following the administration of the vaccine. 
The mainstay in the treatment of severe anaphylaxis is the p rompt use of adrenaline, which can 
be lifesaving.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 67 of 106 Post vaccination, the participant  should remain under the observation of not less than 60 minutes 
for occurrences of immediate or early allergic reactions. Corticosteroids and antihistaminics 
should also b e available in addition to supportive measures such as oxygen inhalation and 
intravenous fluids (IV fluids).   
This being a Phase 1 trial there is no safety data available with the use of MCV -5 vaccine. This 
trial aims to generate the same.  
In clinical tri als of Menactra®, most commonly reported injection site reactions following 
vaccination among adults were injection site pain (53.9%), induration (17.1%), redness (14.4%) 
and swelling (12.6%). In the same population, commonly reported systemic reactions we re 
headache (41.4%), fatigue (34.7%), malaise (23.6%), arthralgia (19.8%), diarrhea (16.0%) and 
anorexia (11.8%) , chills (9.7%) and vomiting (2.3%) . All these are the frequencies reported within 
seven  days of single vaccine dose. SAEs occurred in these ind ividuals at a rate of 1.0% following 
Menactra® vaccine.23 
It is expected that the solicited reactions with adjuvanted and non -adjuvanted MCV -5 would be 
consistent with those reported in clinical trials of Menactra ®. 
Risks from blood draw  
Drawing peripheral  blood can cause discomfort; it might cause minor bleeding and/or bruising 
where the needle enters the skin, and very rarely might cause infection. This risk will be mitigated 
by ensuring that only study staff members who are adequately trained in safe dra wing of blood 
conduct this portion of the study. It is not anticipated that the risks in any one of the vaccine groups 
would be higher than others.  
Risks from participating in a clinical trial  
In addition to the risks described above, all clinical trial pa rticipants are likely to experience 
increased inconvenience due to the visits as they may be of longer duration than standard 
treatment, which might cause more anxiety. They also incur additional risks to their privacy from 
participating in a clinical tria l. This risk will be minimized by ensuring that participant confidentiality 
is maintained by enforcing appropriate data collection, storage, and analysis techniques and 
employing the use of unique identifiers with carefully stored linking files. There may be additional 
risks to study trial participation that we do not know about . 
13.3.  Protocol Review Process  
Scientific review of this protocol will be conducted by PATH , the sponsor of the study . The protocol 
will be submitted under a new IND. Protocol ethical rev iew and oversight will be performed by 
UMB IRB . Continuing review will be undertaken in accordance with existing regulations. The 
Sponsor will be responsible for trial registration at ClinicalTrials.gov.  
Copies of the approved continuing review and final s tudy reports, along with the respective local 
IRB approval notifications, will be submitted to the Sponsor as soon as these documents become 
available.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 68 of 106 13.4.  Participant  Confidentiality  
The PI must ensure that participant  confidentiality is maintained.  Personal identifiers will not be 
included in any study reports. All study records will be kept confidential to the extent provided by 
national and local laws.   
All study procedures will be conducted per GCP guidelines, and every effort will be made to 
protect participant  privacy and confidentiality to the extent possible.  
All study -related information will be stored securely at the study site or at a designated, secure 
off-site location. When not in use and under immediate control of study staff, all participant 
information will be stored in locked areas with access limited to study staff. Data collection, 
process, and administrative forms, laboratory specimens, and other reports will be identified 
exclusively by a coded number to maintain participant  confidentialit y. All local databases will be 
secured with password -protected access systems. Participants’ study information will not be 
released without their written permission, except as necessary for monitoring or compliance with 
legal or regulatory requirements.  
Medical records containing identifying information may be made available for review when the 
study is monitored by the sponsor or an authorized regulatory agency. Direct access may include 
examining, analyzing, verifying, and reproducing any records and repo rts that are important to 
the evaluation of the study.  
13.5.  Reimbursement  
Pending IRB approval, participants will be compensated for their time and effort in this study, and 
be reimbursed for travel to study visits. The study ICF will state the plan for reimbur sement. Study 
participants will not be charged for study vaccinations , research clinic visits, research -related 
examinations, or research -related laboratory tests.  
13.6.  Storage of Specimens  
Stored study research samples (including samples retained for elective analysis) will be labeled 
by a code that only the study site can link to the participant . All stored research samples will be 
logged into a secure database and any use documented. Sampl es may be stored at several 
different repositories and laboratories to complete the analyses required to meet study primary, 
secondary and exploratory analyses. As a part of the informed consent process, participant s will 
be informed of and asked to agree to long -term storage of specimens for use in future, related 
research.  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 69 of 106 14. APPENDICES  
14.1.  APPENDIX I:  Schedule of Events  
Study visit  Visit 1 / 
screening  Visit 2  Visit 3  Visit 4  Visit 5  Final 
Study 
Contact  
Study Day  D-28 to -1 D1 D8+3 D29+14 D85+14 D180±21  
Informed Consent  √ - - - - - 
Demographics  √      
Medical history √ √A √A √A √A √ 
(For SAEs)  
Prior and concomitant 
medications  √ √ √ √ √ 
(For SAEs)  √ 
(For SAEs)  
Physical examination  √ √B √B √B √B - 
Pregnancy test  F  
(female only)  √ √  √ √ - 
Vital signs  √ √ √ √ √ - 
Safety laboratory 
evaluationC 10 mL  - 8 mL  - - - 
Screening for HIV, 
hepatitis B and CD 8 ml     - 
Eligibility criteria  √ √ - - - - 
Randomization of 
eligible participants  - √ - - - - 
Vaccination  - √ - - - - 
Visual inspection of 
injection site   √ √   - 
Memory card review 
and collection  - √ √  - - 
Observe for 60 minutes:  
Assess and record post 
vaccine reactions  - √ - - - - 
Immunogenicity Blood 
collection  - 20 mLE  30 mL  - - 
Cumulative blood 
volume  18 mL  20 mL  8 mL  30 mL    
Adverse event 
reporting   Solicited local and 
systemic reactions   
 Adverse Events   
 Serious Adverse Events  
A. Updated  medical history only  
B. Targeted physical examination, as indicated  
C. Complete blood count (CBC):  WBC, Hemoglobin, Platelets , Chemistry panel:  ALT, Creatinine, Albumin , Total bilirubin  
D. HBsAg , anti -HCV (if positive, by PCR), HIV EIA  
E. Before vaccination  
F. Only in case of female participants  with child bearing potential. At the time of screening a serum pregnancy test will be 
performed whereas on the day of vaccination, urine or serum pregnancy test will be performed  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 70 of 106 14.2.  APPENDIX  II: Toxicity Grading Scale  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 71 of 106 [Replace the following blank pages with the Appendix PDF.]  
  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 72 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 73 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 74 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 75 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 76 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 77 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 78 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 79 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 80 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 81 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 82 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 83 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 84 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 85 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 86 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 87 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 88 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 89 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 90 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 91 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 92 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 93 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 94 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 95 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 96 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 97 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 98 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 99 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 100 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 101 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 102 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 103 of 106   
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 104 of 106  
14.3.  APPENDI X III: References  
 
Reference List  
 
 1.  Stephens DS. Biology and pathogenesis of the evolutionarily successful, obligate human bacterium 
Neisseria meningitidis. Vaccine 2009;27 Suppl 2:B71 -B77. 
 2.  Hedari CP, Khinkarly RW, Dbaibo GS. Meningococcal serogroups A, C, W -135, and Y tetanus 
toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect 
Drug Resist 2014;7:85 -99. 
 3.  Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 
2009;27 Suppl 2:B51 -B63. 
 4.  Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 
2011;86(47) :521-539. 
 5.  Molesworth AM, Thomson MC, Connor SJ et al. Where is the meningitis belt? Defining an area at 
risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002;96(3):242 -249. 
 6.  Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, 
and worldwide epidemiology. J Travel Med 2010;17 Suppl:3 -8. 
 7.  Dbaibo G, El Ayoubi N, Ghanem S et al. Immunogenicity and Safety of a Quadrivalent 
Meningococcal Serogroups A, C, W -135 and Y Tetanus Toxoid Conjugate Vac cine (MenACWY -TT) 
Administered to Adults Aged 56 Years and Older: Results of an Open -Label, Randomized, 
Controlled Trial. Drugs Aging 2013;30(5):309 -319. 
 8.  Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31(1):3 -14. 
 9.  Maiden MC. Th e impact of protein -conjugate polysaccharide vaccines: an endgame for meningitis? 
Philos Trans R Soc Lond B Biol Sci 2013;368(1623):20120147.  
 10.  Altmann D, Aseffa A, Bash M et al. Priorities for research on meningococcal disease and the impact 
of serogr oup A vaccination in the African meningitis belt. Vaccine 2013;31(11):1453 -1457.  
 11.  Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 
2006;19(1):142 -164. 
 12.  Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with 
polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011;10(3):307 -322. 
 13.  Cohn AC, MacNeil JR, Clark TA et al. Prevention and control of meningococc al disease: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm 
Rep 2013;62(RR -2):1-28. 
 14.  Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med 
Microbiol 2002;51(9):717 -722. 
 15.  Sow SO, Okoko BJ, Diallo A et al. Immunogenicity and safety of a meningococcal A conjugate 
vaccine in Africans. N Engl J Med 2011;364(24):2293 -2304.  
 16.  Borrow R, Tang Y, Yakubu A, Kulkarni PS, LaForce FM. MenAfriVac as an Antitetanus Vaccine. 
Clin Infe ct Dis 2015;61 Suppl 5:S570 -S577.  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 105 of 106  17.  Frasch C, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, 
MenAfriVac (TM). Hum Vaccin Immunother 2012;8(6).  
 18.  Kshirsagar N, Mur N, Thatte U et al. Safety, immunogenicity, and an tibody persistence of a new 
meningococcal group A co njugate vaccine in healthy Indian adults. Vaccine 2007;25(Supplement 
1):A101 -A107.  
 19.  Hirve S, Bavdekar A, Pandit A et al. Immunogenicity and safety of a new meningococcal A 
conjugate vaccine in Indian  children aged 2 -10 years: a phase II/III double -blind randomized 
controlled trial. Vaccine 2012;30(45):6456 -6460.  
 20.  Kristiansen PA, Diomande F, Ba AK et al. Impact of the serogroup A meningococcal conjugate 
vaccine, MenAfriVac, on carriage and herd im munity. Clin Infect Dis 2013;56(3):354 -363. 
 21.  Kristiansen PA, Ba AK, Ouedraogo AS et al. Persistent low carriage of serogroup A Neisseria 
meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, 
MenAfriVac. BMC Infect Dis  2014;14:663.  
 22.  LaForce FM, Okwo -Bele JM. Eliminating epidemic Group A meningococcal meningitis in Africa 
through a new vaccine. Health Aff (Millwood) 2011;30(6):1049 -1057.  
 23.  Okwo -Bele JM, LaForce FM, Borrow R, Preziosi MP. Documenting the Results of a Successful 
Partnership: A New Meningococcal Vaccine for Africa. Clin Infect Dis 2015;61 Suppl 5:S389 -S390.  
 24.  Novak RT, Kambou JL, Diomande FV et al. Serogroup A meningococcal conjugate vaccination in 
Burkina Faso: analysis of national surveillance  data. Lancet Infect Dis 2012;12(10):757 -764. 
 25.  Nimenrix Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ -
_Product_Information/human/002226/WC500127663.pdf . 9-2-2015. 4 -4-2016.  
Ref Type: Online Source  
 26.  Menactra Package Insert. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf . 
Food . 2016. 4 -4-2016.  
Ref Type: Online Source  
 27.  Menveo Package Insert. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/A pprovedProducts/UCM201349.pdf . 
2016. 4-4-2016.  
Ref Type: Online Source  
 28.  Ali A, Jafri RZ, Messonnier N et al. Global practices of meningococcal vaccine use and impact on 
invasive disease. Pathog Glob Health 2014;108(1):11 -20. 
 29.  Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Child 2012;97(11):993 -998. 
 30.  Trumenba Package Insert. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf . 
2016. 4 -4-2016.  
Ref Type: Online Source  
 31.  Bexsero  Package Insert. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf . 
2016. 4 -4-2016.  
Ref Type: Online Source  
Study Protocol: ACYWX -001/VAC 046   Versio n 4.0: 2 7 September 2016  
Page 106 of 106  32.  Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of Serogroup B Meningococcal 
Vaccines in Persons Aged >/=10 Years at Increased Risk for Serogroup B Meningococcal Disease: 
Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb 
Mortal Wkly Rep 2015;64(22):608 -612. 
 33.  Jafri RZ, Ali A, Messonnier NE et al. Global epidemiology of invasive meningococcal disease. Popul 
Health Metr 2013;11(1):17.  
 34.  Sow SO, Okoko BJ, Diallo A et al. Supplementary Appendix to: Immunogenicity and safety of a 
meningococcal A conjugate vaccine  in Africans. N Engl J Med 2011;364:2293 -304. 2016. 4 -4-2016.  
Ref Type: Online Source  
 35.  Meningococcal Vaccine Information Statements. http://www.cdc.gov/vaccines/hcp/vis/vis -
statements/mening.html . 2016. 4 -4-2016.  
Ref Type: Onli ne Source  
 
 